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Introduction: Gene therapy is currently being developed for people with cystic fibrosis 
(CF), a life-threatening condition for which there is no cure. The UK CF Gene Therapy 
Consortium are preparing for a multi-dose gene therapy trial of suf icient duration that 
clinical benefit may be seen. 
 
Aims: The current study aimed to explore the expectations and beliefs of cystic fibrosis 
(CF) patients involved in the preparatory phase of the gene therapy trial (the Run-in 




Method: Twelve participants (six with mild and six with moderate CF) were 
interviewed using a semi-structured interview. Intervi ws were recorded, transcribed 
verbatim and then analysed using a Constructivist Grounded Theory approach.  
 
 
Results:  Since entering the Run-in study, half of the patients had increased their 
expectations of gene therapy being an effective future treatment. Most of the 
participants hoped to derive clinical benefit from the trial itself though half were unsure 
of what to expect. Whilst half of the participants expressed the hope of a future cure for 
CF, the remainder saw gene therapy only in terms of an improved treatment. 
Participants used several strategies to manage their expectations including not thinking 




Discussion: The findings indicate that participants in the Run-in trial are generally 
eager to be involved in the gene therapy trial and have developed a strong sense of trust 
in the research team conducting the trials. The levels of optimism expressed for 
personal benefit from trial were higher than those from earlier studies. Some of the 
positive expectations were unlikely to be met by the gene therapy trial and participants 
risk disappointment. However other patients participated with apparently realistic 
expectations and it seems likely that some patients would have participated even 
without prospect for personal benefit. Possible areas of psychological support are 
discussed e.g. a standard clinical interview for all those not accepted for the gene 
therapy trial; screening for anxiety pre-, during and post-participation.  
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1  Introduction 
 
1.1 Overview of CF (CF)  
Cystic fibrosis (CF) is the most common life-threatening recessive genetic disease in 
the UK. It arises due to mutations in the protein of the CF gene i.e. the CF 
transmembrane conductance regulator (CFTR). CF has an incidence of 1 in every 2381 
live births in the UK (Dodge et al., 2007) and currently affects more than 8,000 people. 
Approximately 1 person in 25 in the UK population carries the faulty gene that causes 
CF. There is as yet no known cure for CF. Treatment is palliative and health is 
maintained by treating disease symptoms as they arise (Lowton, 2005). Symptoms 
include bronchopulmonary infections, pancreatic insufficiency and CF related diabetes. 
Treatment involves a range of daily therapies underpinned by chest physiotherapy, 
antibiotics for chest infections and pancreatic enzymes to facilitate food absorption and 
encourage a healthy weight (Morton et al., 2006). Bronchopulmonary infections result 
in progressive lung damage and respiratory disease is the biggest cause of death in the 
CF population (Griesenbach et al., 2006; Parsons, 2005; Wagner & Gardner, 1997).  
 
1.2 Prevalence of CF 
CF is the most common life-threatening genetic disease in the Caucasian population 
(Bossi et al., 2004). There is an estimated birth prevalence in Scotland of one in 1500, 
taking into account both dominant and mild forms of CF (Brock et al., 1998). However, 
there is some variation in the prevalence rates report d. Welsh et al. (1995) state that 
the usual prevalence of CF is 1 in every 2,000 to 3,000 live births in populations of 
European descent.  
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Estimating the birth prevalence of CF is complicated due to the range of severity 
caused by specific heterozygotes (Brock et al., 1998). There is evidence to suggest that 
incidence values vary within distinct geographic areas from 1 in 1,800 to 1 in 8,500 and 
that there is therefore specificity of prevalence for populations (Bossi et al., 2004). 
Although CF affects all races and ethnic groups, the prevalence of CF in Asiatic and 
other non-Caucasian ethnic groups remains extremely low, with one example being the 





1.3.1 Time of Diagnosis 
Since the early nineteen-seventies, newborn screening protocols for CF have gradually 
developed and are now being implemented in 26 countries including the UK (Castellani 
et al., 2009). Diagnosis for CF is now routinely made in infancy. This is by means of a 
heel-prick to sample blood. The sweat test is also used to detect the high level of salt in 
the sweat of people with CF. Prior to this, diagnosis was made based on tests that 
included a sweat test in babies and children who were failing to thrive.  
 
However, there have been differences in screening practice and data collection criteria 
between countries (Farrell, 2008). Although there is no possibility of a single European 
screening approach due to factors such as variations in healthcare resources and ethnic 
mix of populations, the benefit of screening protocls is that more than 3,000,000 
babies are being screened in Europe each year (Castellani et al., 2009). This wider use 
of neonatal screening has improved CF diagnosis in babies (e.g. Bossi et al., 2004). 
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In a comparative analysis of CF Registry data from 2001 from the UK, France, 
Australasia and the USA, the rate of diagnosis of children with CF was 70% in the UK 
and the USA populations respectively compared to 73% in France and 94.3% in 
Australasia (McCormick et al., 2005). Full national neonatal screening was not being 
undertaken in the UK at this stage. By 2007, 33.1% of all recorded diagnoses made 
were at 0 to 3 months compared to later diagnosis i.e. 2.1% of 21 to 30 year olds and 
1.4% of 31 to 40 years olds. The median age of diagnosis was 5 months which 
illustrates that with the introduction of neonatal screening the age of diagnosis of CF 
had fallen considerably which bodes well for treatment.  
 
1.3.2 Late Diagnosis 
When screening is absent there may be a delay in diagnosis, particularly if the clinical 
presentation is uncertain (Widerman et al., 2000). Diagnosis may not occur until 
adulthood amongst those who present with mild or atypical forms of CF (Widerman et 
al., 2000). In a study comparing one group of 27 late diagnosis CF patients (median age 
of 48.8 years at diagnosis) to a group of 28 early diagnosis patients (median age at 
diagnosis was 2 years), those with a late diagnosis had less prevalence of CF related 
diabetes, normal pancreatic function, better nutritional status and milder lung disease 
(Rodman et al., 2005). Just one patient in the late diagnosis group was ∆F508 
homozygous, which is the most common and most potentially severe mutation 
(McAuley & Elborn, 2000, Rana-Diez et al., 2008), compared with ten patients in the 
early diagnosis category. The late diagnosis group dis layed a higher prevalence of 
milder class or unidentified mutations overall (Rodman et al., 2005). However, those 
who are diagnosed late have specific areas in which t ey require support as they adjust 
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to their diagnosis e.g. relationships, family planning and work-related decisions 
(Widerman, 2003).  
1.4 Mutations 
In 1989, the CF gene was identified on chromosome 7 ( .g. Bossi et al., 2004). The 
gene encodes protein to make a chloride channel in the apical membrane of the 
epithelial cells (e.g. Griesenbach et al., 2004a). Currently over 1400 different mutations 
within the gene have been identified (Rana-Diez et al., 2008). However, only a 
minority of mutations have been confirmed as causing d sease (Welsh & Smith, 1993).  
 
CF occurs when a person inherits an abnormal copy of the CF gene from each parent 
and neither copy of the gene can produce functional CFTR protein (e.g. Bossi et al., 
2004, Gozdzik et al., 2005). The most common mutation is delta F508 (∆F508) which 
makes copies of the CFTR protein without phenylalanine, an amino acid usually found 
in position 508 (Riordan et al., 1989). Homozygous patients with ∆F508/∆F508 
demonstrate significantly reduced levels of CFTR function and are associated with 
greater disease severity i.e. CF lung disease, obstructive azoospermia and pancreatic 
insufficiency (McAuley & Elborn, 2000). For heterozygous patients with one copy of 
∆F508, a different mutation affects their second copy f the CF gene (MacDonald et al., 
2007). There is variation in clinical expression of mutations since the second mutation 
may be akin to ∆F508 in eliminating almost all CFTR function or it may have a lesser 
effect (MacDonald et al., 2007). It is estimated that around 90% of people with CF 
have at least one copy of ∆F508 (MacDonald et al., 2007). 
 
The distribution of mutations appears to be specific to race and/or ethnic origin 
(Collazo et al., 2009), with the dominant ∆F508/∆F508 homozygous mutation 
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accounting for 27% of the Italian CF population compared to at least 50% in Northern 
Europe and the United States (Bossi et al., 2004). There is no evidence of the ∆F508 
mutation in the Japanese CF population (Yamashiro et al., 1997). There are 
associations between mutations and disease severity (Rana-Diez et al., 2008) yet 
generally the CF genotype-phenotype association is ot recognised as being strong, 
albeit genotype may predict pancreatic status (Mackie et al., 2003). For example, it has 
been suggested that the rare genotype N1303K increases the risk of diabetes (Cotellessa 
et al., 1996), but this association has not been verified n other studies (Mackie t al., 
2003).  
 
In addition, there is growing evidence that several variants in other genes modify the 
clinical course of CF lung disease i.e. those influencing infection, immunity and 
inflammation control (Buscher & Grasemann, 2006). For example, the TNFAIP gene 
which is involved in inflammation control was associated with better lung function in 
one European sample of 180 children with CF who were ∆F508 homozygous (Buscher 




CF-causing mutations result in loss of function in the transport system of water and salt 
in and out of epithelial cells found in the lining of the lungs, the urogenital tract, the 
sweat glands, and the digestive system (e.g. Brock et al., 1998; Wagner & Gardner, 
1997). Typically the CFTR protein in CF patients transports too much salt and not 
enough water, resulting in sticky mucus which coats and clogs the lungs and alimentary 
tracts (e.g. Boyd et al., 2004; Griesenbach et al., 2004a).  
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1.5.1 Lung Disease 
 
Because the lungs of CF patients do not have a functional mucociliary clearance 
process, whereby particulates like airborne bacteria and viruses are removed from the 
lungs, there is susceptibility to chronic bacterial infection (Wagner & Gardner, 1997; 
Mueller & Flotte, 2008). Infection leads to inflammation which in turn leads to mucus 
plugging, subsequent obstruction and progressive lung damage (e.g. Wagner & Gardner, 
1997). Respiratory function subsequently becomes increasingly reduced and resting 
energy expenditure (REE) is raised (Wilson & Pencharz, 1998). Symptoms include 
high blood pressure in the lungs, coughing up blood an  structural changes in major 
airways. Like adult patients with other forms of severe chronic lung disease (e.g. 
chronic obstructive pulmonary disease), most CF patients will die a premature death 
because of an exacerbation of pulmonary symptoms (Robinson, 2000).  
 
1.5.2 Pancreatic, Gastrointestinal and Liver Disease 
Pancreatic abnormalities are present in 85% to 90% of all CF patients (Lugo-Oliveiri et 
al., 1998). Under-nutrition occurs because of pancreati  insufficiency leading to 
malabsorption of food since the pancreas no longer produces enzymes required to 
digest nutrients (Connett, 2006). Poor absorption of vitamin D can lead to osteoporosis. 
Wilson & Pencharz (1998) highlight that chronic undernutrition, low body weight and 
linear growth failure are recognised difficulties for patients with CF. Thickened 
secretions may result in liver problems with bile ducts becoming blocked, leading to the 
liver not removing toxins from the blood e.g. cirrhosis.  
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1.5.3 Endocrine Disease 
Another complication of CF is CF related diabetes (CFRD) which typically develops at 
around age 20 (Mackie t al., 2003). This is due to loss of the insulin producing islet 
cells in the pancreas. CFRD has similarities to Type 1 and Type 2 diabetes and it is 
recognised as one of the main non-pulmonary complications of CF and a contributory 
factor in premature death.  
 
1.5.4 Other Symptoms 
For men with CF, there is almost universal azoospermic infertility due to congenital 
bilateral absence of the vasa deferentia (Mackie et al., 2003), with 98% of men with CF 
requiring assisted conception or donor sperm for conception (Boyd et al., 2004). For 
women, however, the chances of pregnancy are good and even better when a patient 
has good respiratory health (Boyd et al., 2004). Further complications include 
osteoporosis and pancreatitis. Whilst there is no primary renal disease, side-effects from 
medications such as aminoglycoside antibiotic therapy can adversely affect renal 
function and may be a contributory factor for peripheral neuropathy (Mackie t al., 
2003).  
 
1.6 Current Treatment 
Treatment focuses on preventing deterioration of the lungs through the use of 
physiotherapy, antibiotics and improved nutrition. A multi-disciplinary approach is 
utilised with the level of intervention dependent upon disease severity. Typically, 
physiotherapy is used to help keep the patient’s airways clear. The use of antibiotics 
reduces colonisation by bacteria and anti-inflammatory drugs are used to minimise 
tissue damage. Because of malabsorption, pancreatic enzymes and fat-soluble vitamins 
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are used respectively to aid digestion and raise vitamin levels to as near normal as 
possible (e.g. Morton et al., 2006). To help with weight gain, high calorie and high 
protein food are taken and CF patients are encouraged to eat 120 to 150% of the daily 
allowance recommended for normal individuals (Wilson & Pencharz, 1998). When 
appropriate, overnight feeding is used to encourage weight gain. There is growing 
recognition that effective interventions are required for CF related diabetes and 
osteoporosis (Dobbin & Bye, 2003). However, there is also growing expectation that 
increased knowledge of the molecular biology of CF mutations will lead to improved 
treatments e.g. repairing the CFTR protein function, thereby reducing illness, 
improving quality of life and increasing life expectancy (MacDonald et al., 2007).  
 
1.7 End-stage Disease 
When a person with CF has end-stage lung disease (i.e. lung function that is less than 
30% of function predicted for someone of the same ag , gender, weight and height), 
bilateral lung transplantion becomes the most viable therapeutic option for prolonged 
survival (Meachery et al, 2008). This is in spite of strict acceptance criteria for 
transplantation (e.g. Schidlow, 2000), and a shortage of donor lungs. Despite potential 
complications including risk of infection and organ rejection (Studer et al., 2004; 
Taylor et al., 2008), survival rates in the UK have increased, being 82% at one year, 
70% at three years and 51% at ten years (Meachery et al., 2008).  
 
1.8 Life Expectancy 
Before 1960, the average life expectancy for CF patients was under five years of age 
(Wagner & Gardner, 1997). Improved treatment has had a positive impact upon life 
expectancy and children with CF are increasingly surviving into adulthood (Dobbin & 
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Bye, 2003). Outcomes for patients with CF now vary from early death due to lung 
disease through to a normal life span, though the latt r is rare (NIH, 1997). In the U.K. 
the most recent median predicted age of survival is 35.2 years (UK CF Registry, 2007). 
This compares with 36.4 years in France and 37.4 years in Germany and the U.S. 
(Buzzetti et al., in press). However, accurate comparison with other data sets is 
problematical due to differing methods of acquiring i formation on CF populations 
(Dodge et al., 2007). For all UK CF patients, the median life exp ctancy is more likely 
to be 50 years for those born in 2000 (Dodge et al., 2007). There is also evidence to 
suggest that the condition of patients at the time of diagnosis strongly influences 
prognosis (Lai et al., 2004). 
 
1.9 Psychological Impact of Having CF 
Despite advances in treatment, CF is still associated with psychological adversities for 
the patient (Casier et al., 2008). There have been many studies to assess th prevalence 
of depression and anxiety in the CF population with conflicting evidence about whether 
there is an association between having CF and psychological functioning (Pfeffer et al., 
2003). In some studies, adult CF patients show psychological functioning that is similar 
to that of physically healthy controls (e.g. Anderson et al., 2001; Blair et al., 1994). In 
one study young adults with CF seem less prone to developing mental health 
difficulties than their physically healthy peers (Szyndler et al., 2005). One of the 
reasons for the discrepancies in these studies may be the fact that older studies are 
rapidly becoming invalid due to the fact that life expectancy has changed so 
significantly in the past forty years. This has brought about by changes in the treatment 
and management of CF (Pfeffer et al., 2003).  
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The current consensus points to people with CF as falling within the normal population 
distribution regarding psychological functioning until a point where disease severity 
becomes significant (Pfeffer et al., 2003; Riekert et al., 2007; Sawicki et al., 2008; 
Szyndler et al., 2005). There is also the consensus that people with CF may have to deal 
with certain disease specific issues that may need or benefit from psychological support 
(Anderson et al, 2001). 
 
 
Living with Uncertainty   
It has been suggested that being able to live with the unpredictable and uncontrollable 
nature of CF requires the ability to tolerate uncertainty (Casier et al., 2008). This 
applies to specific issues e.g. predicting whether cur ent lung infection will prove to 
have fatal consequences (Robinson, 2000) or waiting for a lung transplant (Limbos et 
al., 2000; Vermeulen et al., 2005) as well as more general issues such as coping with 
the life-limiting nature of CF. 
 
Some studies have shown that having to tolerate uncrtainty can produce anxiety and 
depression in people with CF (e.g. Havermans et al., 2008) although not all studies 
have reported this outcome (e.g. Pearson et al., 1991; Pfeffer et al., 2003). These 
findings point to the fact that all people with CF have to tolerate a variety of forms of 
uncertainty, with some finding this more difficult than others. Indeed in a study of lung 
transplant recipients it was found that strategies employed to manage uncertainty, 
namely focusing on the present, resulted in participants experiencing a stronger sense of 
self in the post transplant period (Durst, 2001).  
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Quality of Life   
As most people with CF are now surviving into adulthood, the issue of quality of life 
becomes an important issue in the absence of a cure for CF. A number of studies have 
investigated this. As above, these studies have highlighted that there was little 
difference in quality of life between healthy controls and CF patients until disease 
severity increased (Pfeffer et al., 2003; Sawicki et al., 2008; Wahl et al., 2005). 
However, it is accepted that people with CF also have to manage the demanding 
regimen of intensive daily treatments (Casier et al., 2008).  
 
Depressive symptoms are also associated with poorer quality of life and this indicates 
that screening for depression and appropriate treatment may improve health-related 
quality of life for patients with CF (Riekert et al., 2007). Wahl et al. (2005) suggest that 
further research is needed to gain knowledge of the effect on quality of life of living 
longer with CF and on how to promote quality of life for those living with a life-
threatening disease.  
 
Role of Psychologist 
A specialist clinical psychologist can help adults with CF to find the best personal way 
to cope with CF (Oxley & Webb, 2005). This involves not only addressing 
psychological needs that may be specific to an indiv dual or their stage of disease, but 
may also involve screening for anxiety and depression. This is important as anxiety and 
depression have been recognised in other long-term conditions as risk factors for 
increased use of the health care system, poor adherence to treatment and increased 
mortality. Havermans et al. (2008) suggest that anxiety and depression screening could 
be used to target areas of clinical need and thereby prevent these risk factors. Indeed, 
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the CF Trust recommend that all CF centres have accss to a specialist CF clinical 
psychologist who co-ordinates routine screening of anxiety and depression as well as 
administering a validated quality of life measure as p rt of ongoing annual review tests 
(CF Trust, 2001). 
 
1.10 Gene Therapy  
 
Gene therapy research is currently taking place into ts application to over twenty 
diseases (Meneguzzi et al., 2007). Researchers have observed that no one specific gene 
transfer agent (GTA) is suitable for all genetic diseases, but that disease-specific gene 
therapy is required (Griesenbach & Alton, 2009). Researchers have acknowledged the 
need for further study of the immune response to GTAs, but following the unfortunate 
death in 1999 of an 18 year old male patient participating in a non-CF pilot trial of gene 
transfer, they have proceeded with caution (Raper et al., 2003).  
 
Gene Therapy for CF 
Since the discovery and subsequent cloning of the CF transmembrane conductance 
regulator (CFTR) gene in 1989, CF has been an attractive target for gene therapy 
research (Mueller & Flotte, 2008). Early enthusiasm for the novel area of gene therapy 
in the 1990s led to a concerted effort by academics and clinicians to apply CF gene 
therapy (Mueller & Flotte, 2008). It was felt that “considerable progress” had been 
made (Middleton & Alton, 1998, p.197). The CF Trust currently spends just over 75% 
of its annual budget to research in gene therapy, with the remainder being spent on 
research into other features such as drug therapy and inflammation (CF Trust, 2009). 
However, gene transfer therapy is significantly more complex than was first understood 
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and to date, there are no approved therapies targeted at the CFTR protein (Pearson, 
2009).  
 
CF Gene Therapy Studies to Date  
A review of relevant empirical studies provides thecontext and the rationale for the 
present qualitative study.  
 
 
As a disease with a single gene defect, CF is likely to be targeted more efficiently than 
diseases involving multiple genetic locations (Griesenbach & Alton, 2009). Most 
research is focused on the respiratory system due to the greatest pathophysiology being 
within the lung (e.g. Wagner & Gardner, 1997). Since 1989, 25 phase I and II clinical 
trials have been undertaken, with most of the early trials targeting nasal epithelium as a 
lung surrogate in order to test access and sampling (Griesenbach & Alton, 2009). The 
trials in the early 1990s served to establish proof-of-principle for the gene transfer to 
the epithelial lining cells of the lungs (Griesenbach et al., 2004b). There is also 
evidence of partial correction of chloride transport in several clinical studies undertaken 
(Griesenbach & Alton, 2009). One such trial involved the gene transfer agent (GL67) 
being administered to the lungs for the first time (Alton et al., 1999). These early 
studies provided further support for the possibility of gene therapy for patients with CF 
(Griesenbach et al., 2006).  
 
Requirements of effective gene therapy for CF 
Effective gene therapy treatment for CF airway disease requires the development of 
gene transfer agents that can penetrate the airway epithelial cells’ defence mechanisms 
against foreign bodies (e.g. Boucher, 1999; Koehler et al., 2001). Set within the reality 
of the lungs being routinely infected by pathogens, it is theoretically possible to 
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develop gene therapy treatment that can cross the lung’s defences (Koehler t al., 2001). 
However, this defence response has been underestimated, engendering the need for 
improved knowledge of host cells’ interaction (Griesenbach & Alton, 2009). An 
efficient transfer agent is needed to maximise gene transfer whilst being able to 
minimise hostile immune responses to the agent and to be able to deliver repeat 
administrations of gene therapy (Koehler et al., 2001).  
 
New strategies are being developed to improve the efficiency of gene therapy delivery 
and the length of time the gene remains in the lung (Griesenbach & Alton, 2009). 
Clinical trials of sufficient duration with adequately powered sample sizes are required, 
as is repeated administration of a gene therapy agent to correct the defective gene 
(Griesenbach et al., 2006; Griesenbach & Alton, 2009). Clinical studies require clear 
endpoints and outcome measures that are specific to people with CF (Lee & Southern, 
2009). Griesenbach & Boyd. (2005) suggest the most important endpoint in later trials 
is stabilisation of lung function, albeit this may be somewhat difficult to measure as 
those with good function will be the most likely to respond successfully to gene therapy. 
Griesenbach & Boyd (2005) also suggest the use of a validated quality of life 
questionnaire to elicit feelings and opinions of patients in order to gain valuable 
information about the progress of gene therapy trials. A further factor is patient 
selection since CF gradually damages the airways and ge e therapy may prevent or 
reduce further damage but will not repair damage. As such, gene therapy “will likely be 
most efficient and beneficial in young children with well preserved airways” although 
biomarkers may be harder to identify in their relatively unaffected lungs (Griesenbach 
& Alton, 2009, p.134).  
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CF has been genetically replicated in mice (e.g. Hilliard et al., 2008) and in pigs 
(Rogers et al., 2008) with the aim of understanding how CF develops e.g. whether 
infection precedes airway inflammation or vice versa. Whilst both animal models have 
provided data regarding CF, mice do not develop the lung disease found in humans and 
it is still not clear how lung disease will develop in pigs (Rogers et al., 2008). It is 
therefore premature to use animal models in gene therapy trials that target the lung. 
Consequently, human trials are required to be undertak n with consenting participants.  
 
CF Run-in Study 
The UK CF Gene Therapy Consortium designed the Run-in study as the pre-treatment 
selection phase for participants and for establishing baseline measurements for a 
subsequent gene therapy trial (See below). Participants on the Run-in study are aged ten 
upwards but because of ethical considerations, the curr nt study was restricted to adults 
i.e. aged sixteen and older.  
 
The Run-in study will develop understanding of how CF changes over time, thereby 
helping researchers to select the best methods of measuring changes in the lung in the 
gene therapy trial. Criteria for patient selection will also be developed. The Run-in 
study started in February 2008 and participants’ entry onto this has been staggered. 
Participants in the Run-in study attend four visits over a one-year period and each visit 
lasts for approximately three hours. During the study visit, participants are asked to 
undertake a series of tests to measure lung function. Those who have participated in the 
Run-in study will be considered for selection to the gene therapy trial currently 




Gene Therapy Trial 
Preparations are now being made for the multi-dose gene therapy trial, which will be 
placebo-controlled and double-blinded (Griesenbach & Alton, 2009). It is expected to 
be the biggest gene therapy trial undertaken to date for CF (Pearson, 2009).The purpose 
of the trial is to assess whether the non-viral gene therapy agent Genzyme lipid 67 
(GL67) can be delivered safely to the lungs over a period of time and whether it 
improves clinically appropriate endpoints like infection, inflammation and lung 
function (Griesenbach & Alton, 2009). A single dose pilot is being used to assess the 
safety and length of gene expression in the lungs before the multi-dose GL67/DNA 
complexes are administered over a twelve-month period. It is anticipated that there will 
be approximately fifty participants in the active tr atment group and fifty participants 
receiving the placebo.  
 
Based on rational scientific principles, it is also anticipated that the treatment is likely 
to work best in those with early disease and therefore particularly well in children 
(Griesenbach & Alton, 2009; J.A.Innes, personal communication, 24 June 2009). It 
would be harder to correct the gene in those with advanced CF because of more severe 
lung disease i.e. secondary chronic bacterial infection and associated scarring of the 
lung membrane. However, the magnitude of any clinical benefit from the trial is as yet 
unknown and the trial is designed to allow investigators to look for changes that 
indicate clinical benefit (J.A.Innes, personal communication, 24 June 2009).  
 
 
The Research Community’s Expectations of CF Gene Therapy Trials 
 
In a paper on the status of gene therapy for CF, Richard Boucher wrote in 1999:  
 
 “ Despite an impressive amount of research in this area, there is little  
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  evidence to suggest that an effective gene-transfer approach for the 
  treatment of CF lung disease is imminent (p.441).”  
 
Because developing CF gene therapy has taken longer a d has been more complex than 
anticipated, there has been a reduction in academic and industrial interest in CF gene 
therapy over the past ten years (Griesenbach & Alton, 2009). Although progress within 
gene therapy for CF has taken longer than anticipated, and indeed has been described as 
slow, CF is not alone since this is representative of the field of gene therapy generally 
(Parsons, 2005). In terms of development, one approch is to compare its progress to 
the development of other medical advances such as vaccines or antibiotics. Within this 
context, the development of a successful medical tehnology is expected to take longer 
than that of a drug developed within an established t rapeutic system (Parsons, 2005).  
 
It is recognised that the progress of clinical trials does not initially match advances in 
preclinical research (Griesenbach et al., 2004b). Rapid progress in CF gene therapy was 
initially anticipated due to proof in principle of non-invasive access to lung epithelial 
cells, but this still presents a challenge in practice (Griesenbach et al., 2004b). Whilst 
there have been no dramatic clinical benefits to date, the gene therapy pre-clinical and 
clinical studies have provided significant information that has informed gene transfer 
technology and has helped with understanding the def nc  mechanisms that impede 
efficient delivery (Mueller & Flotte, 2008). The potential benefits of successful delivery 
of gene therapy are motivating factors in overcoming the current barriers.  
 
Expectations of Gene Therapy within the CF Population 
 
As difficulties in developing gene therapy have been ncountered since 1989, hopes of 
the potential of this treatment have fluctuated in CF patients and their families. There is 
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some evidence for CF patients having more awareness of gene therapy compared to the 
wider population (Iredale et al., 2003). The media has been shown to influence 
participant knowledge regarding experimental gene therapy (Blair et al., 1998) and 
participants in trials and the general public are susceptible to misinterpreting 
preliminary data and thereby to developing unrealistic hopes and expectations (Skach, 
2002). 
 
Writing ten years ago, Dodge (1998) was of the opini n that people with CF had 
unrealistic hopes of the potential of gene therapy. Dodge (1998) posited that the 
“delivery of gene therapy cannot be guaranteed” (p.158), therefore emphasis should be 
placed upon improving existing treatments and developing new pharmacological 
approaches. Patients with CF have benefited from clinica  advances and this, as well as 
knowledge of research currently being undertaken into new treatments, has led to 
increased hope and expectation of effective treatment for CF (Dobbin & Bye, 2003). 
There is, however, increasing confidence in gene therapy becoming a safe and 
successful treatment (Davies t al., 2001; CF Today 2005/2006). In a study considering 
the ethics of children participating in children’s gene therapy trials (Jaffe et al., 2006), 
82% of parents surveyed believed gene therapy to be the most important area of 
research for those with CF. The prospect of gene therapy treatment being developed 
offers hope to both CF patients and their families and it is proposed that this prospect 
helps them to feel less afraid of the future (Gotz & Gotz, 2000).  
 
 
Although there has been disappointment about the unc rtainty regarding the application 
of gene therapy (Gotz & Gotz, 2000), researchers, patients and families still have an 
investment in seeing a positive outcome. As barriers to effective gene therapy are 
overcome, the following hope may be realised: 
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 “CF researchers, clinicians, parents and patients will increasingly be  
 able to imagine a time when a child growing up with CF will breathe  
 with lungs similar in function to the lungs in normal children.”   
 (Parsons, 2005, p.96) 
 
 
Participant Expectations of Gene Therapy in Gene Therapy Trials 
 
There has only been one published study to date on a CF gene therapy trial that has 
investigated psychological factors involved in participation (Blair et al., 1998). 
Qualitative and quantitative methods were used to assess the expectations, knowledge 
and psychological functioning of sixteen CF participants in a single dose nasal gene 
therapy phase I safety trial (Blair et al., 1998). As reported in the study “most 
participants” had a realistic understanding that they could not expect personal clinical 
benefit from participating on the safety trial. Whilst it is unclear how many participants 
this constituted, it was also reported that thirteen participants expected to benefit 
personally from gene therapy in the future. This led r searchers to conclude that 
participation in the trial led to slightly raised expectations of personal future benefit.  
 
 
A more recent study was undertaken by Thomas et al. (2007). This was the first 
empirical investigation of whether adults with CF had realistic expectations of gene 
therapy. A single-site investigation of patients’ knowledge and opinions of gene 
therapy for CF was undertaken with 72 adults completing questionnaires. This covered 
whether patients’ knowledge of gene therapy was realistic, what their sources of 
information on gene therapy were, whether patients wished to know more about gene 
therapy and what their expectations of gene therapy were. Amongst the findings was 
that 46% of respondents believed that receiving gene therapy treatment for themselves 
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was unlikely but 77% believed that that children under five and the unborn were most 
likely to benefit. 
  
 
No participant was enrolled on a gene therapy trial. This study was replicated and 
extended to cover four sites and participants completed a clinic-based questionnaire 
which yielded both quantitative and qualitative data. The findings have been presented 
at the European CF Conference (Richards et al., 2008) and the study is currently being 
written for publication in full (A. Duff, personal communication, 17 June 2009). 
Although 75% of participants indicated interest in how gene therapy might work and 
74% were interested in its potential benefit for them, none of the 266 participants was 
participating on a clinical trial for gene therapy (A. Duff, personal communication, 17 
June 2009). This leaves a gap in knowledge regarding what participants with CF expect 




1.11 Rationale for the Current Study 
   
Patients with CF are closer to gene therapy than ever before. The gene therapy trial is of 
importance because of the amount and type of data it will generate as the biggest gene 
therapy trial to date. It is also the first trial of its kind that will give participants gene 
therapy on multiple occasions, which may result in cli ical benefit. However, the 
magnitude of any clinical benefit from the trial is a  yet unknown and the trial is 
designed to allow investigators to look for changes that indicate clinical benefit 
(J.A.Innes, personal communication, 24 June 2009). 
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Expectations of the participants in the Run-in study have not been explored regarding 
outcomes of the gene therapy trial. There has been no study to date exploring the 
psychological impact of participants in a preliminary trial awaiting selection for a gene 
therapy trial. The current study will therefore provide data from participants recruited to 
the Run-in study in which medical measurements and participants are being selected for 
the gene therapy trial 
 
1.12 Aims of this Study 
 
The current study aimed to discover the following: 
 
1. Expectations that participants on the Run-in study had of participation in the gene 
 therapy trial. 
2. Any misconceptions that participants may have had of gene therapy treatment. 
3. Participants’ general expectations of gene therapy. 
4.  Whether participants’ expectations of gene therapy treatment had changed since 
 they started participating in the CF Run-in study. 
5.  Whether participants had experienced any physical or psychological difficulties 
 or benefits whilst participating on the Run-in study. 
 
This study also aimed to identify whether there were any particular areas in which 
participants required psychological support e.g. if not selected for the gene therapy trial. 
Qualitative methodology was selected to allow for exploration of these aims and to 




It was hoped the current study would make a small contribution to the evidence base by 
discovering expectations that participants currently participating in the Run-in study 
had of the trial and of gene therapy in general. This was a novel area of research with 
such a cohort. It was also hoped that the study would identify psychological factors 
involved in the process of anticipating selection fr the trial.  
 
 28 
2  METHOD 
 
This chapter provides an overview of the research design and methodology selected for 
the study. It also outlines how the quality of the research was managed in terms of 
transparency and rigour.  
 
2.1 Research Design 
The main aims of the study were to discover the expectations that participants resident 
in Scotland and northern England recruited for the CF Run-in study had of the gene 
therapy trial and of gene therapy in general and to ascertain whether these expectations 
changed during their participation in the CF Run-in study.  
 
It is important that the research method selected is appropriate for the questions being 
investigated (Barker et al., 2002). A qualitative rather than a quantitative approach was 
chosen since it can uncover the nature of people’s experiences and perspectives as yet 
little explored in research (Parker, 2005). There has been little research into 
psychological factors involved in participation in gene therapy trials for CF. It was 
anticipated that a richer description of participants’ expectations would be yielded by 
using a qualitative approach than by using the fixed response options of a quantitative 
measure.  
 
Following Burman (1994), a semi-structured interview was designed to allow for 
exploration of issues that might be too complex or not be sufficiently identified to allow 
investigation by quantitative methodology. A well designed semi-structured interview 
with appropriate use of open questions allows for the generation of a wide range of 
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responses (Parker, 2005). Because it is semi-structured, it is also an open and flexible 
research tool (Burman, 1994). A semi-structured interview was selected as a 
methodological tool to allow the interviewer to respond sensitively to participants’ 
concerns as they arose through interview and thus also record perspectives that were 
not anticipated, thereby enhancing the richness of the data.  
 
2.1.1 Grounded Theory 
The current study was based on the constructivist version of grounded theory proposed 
by Charmaz, which acknowledges that the researcher aims towards an interpretive 
understanding of the data (2000). Following this philosophy, knowledge is mutually 
created by both the researcher and the research participant (Charmaz, 2000). The 
current study also draws upon guidelines set out by Strauss & Corbin (1998). The 
rationale for the researcher’s choice of approach is outlined below with the 
qualification that there is a degree of flexibility n the use of grounded theory methods 
(Annells, 1997; Charmaz, 2006; Glaser and Strauss, 1967). 
 
2.1.2 Epistemological Issues 
The choice of a particular research method can be influenced by the researcher’s 
epistemological position on how knowledge is understood and reached. For example, 
there may be a bias towards a positivist, quantitative approach if a researcher believes 
that empirical methods uncover an objective reality (Murray & Chamberlain, 1999). 
Yet there is an increasing challenge to the claims of objectivity in the positivist 
paradigm (Murray & Chamberlain, 1999). Whilst this debate is outside the scope of the 
current study, it is important to acknowledge that researchers are located within a 
diversity of perspectives and assumptions. However, th  researcher should be guided in 
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the choice of research methods by the nature of the res arch question (e.g. Strauss & 
Corbin, 1998). The research method itself should not be held in special regard (Barker 
et al., 2002) such that:  
 
“A thousand-word description is no more valid a “picture of the person” than a single 
score on a standardised test.” (Gergen & Gergen, 2000, p.1027). 
 
 All methods have their relative advantages and disadvantages and therefore an 
informed choice can be made about the best fit betwe n purpose of the study and 
method (e.g. Barker et al., 2002; Kvale & Brinkmann, 2009). A qualitative approach 
was selected for the current study (See Section 2.6.1: Approach to Conducting a Semi-
structured Interview) after formulating the research questions and clarifying the 
purpose of the study (Kvale & Brinkmann, 2009). Whilst the researcher was aware that 
both Interpretive Phenomenological Analysis (IPA) and grounded theory could capture 
the nature of participant expectations of gene therapy and had structured guides for 
novice qualitative researchers, she chose a grounded theory approach because she also 
wanted to map social processes in the nature of partici tion in trials (Charmaz, 1995; 
Dallos & Vetere, 2005). The researcher was aware that if not conducted analytically in 
order to develop theory, the approach could yield a escriptive, systematic map of 
concepts and categories (Willig, 2001). However, Charmaz (2006) has also highlighted 
that a grounded theory approach is valuable for producing descriptive studies, although 
descriptive findings do not result in hypotheses or make explicit predictions.  
 
2.1.3 Grounded Theory Methods 
Grounded theory methods were originally outlined by sociologists Glaser and Strauss in 
the 1960s. Grounded theory was developed as a challenge to the prevailing quantitative, 
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positivist practice in which hypotheses were logically deduced from existing theories 
(Charmaz, 2006, p.4). Qualitative methods were often used in the initial stages of 
research in order to refine quantitative methods for subsequent more “rigorous” 
research (Charmaz, 1995, p.29; Charmaz, 2006). Glaser and Strauss (1967) proposed a 
revolutionary, systematic and concurrent approach to data collection and analysis in 
order to develop novel theories from research that is grounded in, or drawn from, the 
data.  
 
Different schools of thought have arisen concerning grounded theory methods. Strauss 
and Corbin’s (1990) co-authored work Basics of Qualitative Research: Grounded 
Theory Procedures and Techniques r fined the techniques of grounded theory. There is 
some debate as to whether this book and the later second edition of their work (Strauss 
& Corbin, 1998) develops grounded theory methods or offers technical procedures that 
are essentially different from the original conception of the method (Charmaz, 2000). 
Although Glaser (1992) vigorously contested the formulaic techniques of Strauss and 
Corbin, the latter’s techniques may help novice researchers to better understand the 
process of data gathering and asking questions of the data (Charmaz, 2000). The 
approach of Strauss and Corbin leans towards a positivist stance in which data is seen 
as being real yet it also recognises interpretation of data by the researcher. The stance 
of Charmaz (2000) is that the data are reconstructions of experience rather than the 
actual experience itself. Therefore the researcher’s interpretation of the area under 
study is in essence a construction rather than an objective reality to be discovered 
(Charmaz, 2006). This researcher recognises that interv ews themselves may contain 
constructions, with any interpretation of these being constructions of constructions.  
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2.1.4 Process of Grounded Theory 
The analysis begins with the process of coding emerging data as it is collected. 
Therefore data collection and data analysis are concurrent. Coding involves studying 
the data in order to separate it into discrete labels for each action, event and process. As 
such, coding emerges from the data with categories being created of actions, events and 
processes which share common features or characteristics (Charmaz, 1995, p.37). 
When categories are descriptive they work as “descriptive labels.” As the process of 
analysis develops, the researcher identifies categories at a more abstract “analytic” level 
which interpret examples of data (Willig, 2001, p.33). Categories are conceptual in the 
sense that they are defined specifically in terms of their properties i.e. characteristics or 
attributes (Dey, 1999).  
 
Using a process known as constant comparative analysis, the researcher identified 
similarities and differences regarding emerging categories (Willig, 2001). Comparisons 
were made within the same individual’s account, betwe n different individuals, and 
between data within separate categories (Charmaz, 1995). This allowed for the 
construction of subcategories and for the integration of subcategories into categories. 
The researcher looked for instances of “negative cas s” where instances did not fit into 
emergent categories (Willing, 2001, p.35). This set limits on the emerging theory and 
allowed it to represent the complexity of the data from which it was drawn (Willig, 
2001). Following the suggestion by Charmaz (2006) for memo-writing, the researcher 
successively maintained notes of research and analysis which prompted the researcher 
to a more analytic level of theory development.  
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Theoretical sensitivity occurs when the researcher is sensitised to the data in terms of 
how to modify or enrich the emerging theory. Theoretical sampling occurs when the 
researcher is refining categories and discovers gapin the data which require more data 
in order to make categories more definitive and therefore refined (Charmaz, 2000). It 
also serves to define the links between categories (Charmaz, 2000). Finally, theoretical 
saturation occurs when no new categories are constructed and existing categories can 
no longer be questioned or expanded (Willig, 2001). Some have questioned whether 
pure saturation can realistically be achieved (Dey, 1999; Willig, 2001; Charmaz, 2006) 
but a reasonable approximation to theoretical saturation may be an achievable goal.  
 
2.2 Research Tools 
 
2.2.1 Demographics Sheet  
This was designed by the researcher to gather basic demographic information about 
participants. The information was gathered from interviews and from Run-in study 
notes under supervised access by the research team. The information included date of 
birth, time of diagnosis and lung function at the first Study Visit. It cannot be included 
in full here because of confidentiality issues. However, an outline of the demographics 
sheet has been included as an appendix (See Appendix 1) and information from it has 
been presented in the Results (See Section 3.1: Particip nt Information, Table 1). As 
time of diagnosis would have indicated disease severity and may have influenced the 
researcher’s expectations regarding the interviews, these details were only confirmed 
after interviews had taken place. This was in order for the researcher to ask questions 
that were not influenced by prior anticipation of the participant’s response.  
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2.2.2 Semi-structured Interview  
A semi-structured interview schedule was compiled by the researcher and consisted of 
five core questions. This schedule offered a useful str cture for the researcher, who was 
new to qualitative research, since initial questions devised in advance can ensure the 
avoidance of leading questions or of questions that would result in minimal responses 
(Smith, 1995). The five core questions were devised to address the aims of the research. 
However, in keeping with a grounded theory approach, processes of data collection and 
data analysis were linked throughout the research process to develop theory (e.g. Glaser, 
1992). Thus the researcher developed or revised questions for subsequent interviews 
that enabled further exploration of emerging categori s (e.g. Glaser, 1992). This 
included additional ways of asking the same question to facilitate exploration. A copy 
of the schedules used in interviews with Participant 1 and 12 is enclosed in Appendix 2, 
with additions to the schedule in italics. 
 
 
Questions from a previous study of expectations of gene therapy in CF were considered 
in developing the current questions in the semi-structured interview (Blair et al., 1998). 
The researcher amended these questions to facilitate exploration of issues relevant to 






1. Aim: To discover participants’ expectations of the gene therapy trial. 
 
 Question: If you are selected for the gene therapy trial, what do you  
  expect the outcome of the trial to be for you personally?  
 
2. Aim: To discover any misconceptions that participants may have  
  of gene therapy. 
 
 Question: What do you know about gene therapy? 
 
3. Aim: To discover the wider expectations that participants have of  
  gene  therapy. 
 
 Question: What difference do you think that gene therapy treatment  
  will make to the lives of people with CF in the future? 
 
4. Aim: To discover if participants’ expectations of gene th rapy  
  treatment have changed since starting on the Run-in study. 
 
 Question:  Have your expectations of gene therapy treatment changed  
  since you started participating in the CF Run-in study? 
 
5. Aim: To discover any difficulties (physical or psychological) or  
 benefits that people experience whilst participating in the  
 Run-in study for the gene therapy trial. 
  




Figure 1.1: Questions addressing study aims 
 
 
2.3 Ethics  
 
Before any research with participants is undertaken, co sideration must be given to 
ethical implications arising throughout the research process. Participants are to be 
protected from harm at all times, with the added aim of preserving their psychological 
well-being, health, dignity and values (Tindall, 1994, p. 152). Because this study aimed 
to ask participants with CF potentially sensitive questions, very careful attention was 
given to ethical issues during the process of reseach design. This helped to sensitise the 
researcher to areas which required careful thought and to ensure that the research was 
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undertaken in accordance with the ethical standards of the University of Edinburgh 
(2002) and the British Psychological Society (2005).  
 
 
2.3.1 Ethical Issues  
The researcher considered the following closely intertwined ethical issues relevant to 
this research:  
o Acquiring informed consent 
 
o Guaranteeing confidentiality 
 
o Managing participants’ potential fatigue 
 
o Managing potential distress of participants 
 
o Considering potential non-selection for the gene therapy trial 
 




2.3.2 Acquiring Informed Consent 
To facilitate mutual respect and to undertake research with integrity, there needs to be 
full disclosure to the participants of the nature of the research. This involves the role of 
the researcher, the purpose of the research, the requirements of participation, the style 
and length of interview, the number of participants being recruited and the management 
and use of data (Tindall, 1994).  
 
To facilitate informed consent, a Patient Information Sheet (See Appendix 3) and an 
invitation letter (See Appendix 4) were sent to all identified patients participating on the 
Run-in study (See Section 2.5.4: Recruiting Identified Participants). Patients had at 
least one week to read the information regarding the s udy and to discuss any questions 
or issues with friends, family members, the researcher or any relevant professional 
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before deciding whether or not to participate (See ction 2.5.4: Recruiting Identified 
Participants). In addition, potential participants were given the contact details of a 
Consultant Physician in Respiratory Medicine, who was available to provide 
independent information about the research study. 
 
All patients had given informed consent for participat on in the Run-in study. These 
patients had already been screened to ensure that none had a history of cognitive 
difficulties or severe psychiatric illness. Participants in the current study indicated that 
they wished to participate by telephone or by using the response slip on the invitation 
letter (2.3.4 Recruiting Identified Participants). When meeting participants, prior to any 
interview being undertaken, the researcher ensured that any questions about the study 
were answered and that the participant understood the role of the researcher, the nature 
of the study and the nature of participation. Participants were informed of the number 
of participants recruited and of the management and treatment of data and results.  
 
The researcher also informed participants of their right to withdraw from the current 
study at any time. The researcher reiterated that con inuing or future care was not 
dependent upon participation in the interview. She also reiterated that she was not part 
of the CF Run-in research team and that any selection procedures for the gene therapy 
trial would not be influenced by their participation r otherwise in the current study. It 
was ascertained by the researcher whether consenting patients still wished to be 
interviewed. A consent form was then completed and signed by participants and 
counter signed by the researcher (See Appendix 5). The researcher was not involved in 
the clinical care of any of the participants in theRun-in study.  
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2.3.3 Guaranteeing Confidentiality 
Patients were informed via the Patient Information Sheet that the interviews would be 
strictly confidential. Although the patients’ hospital consultants and general 
practitioners (GPs) were informed of patients’ participation in the study (See Appendix 
6), the content of interviews remained strictly confidential. At the research interview, 
the procedure of protecting confidentiality was reiterated with the exception of where 
there were issues for the safety or wellbeing of the patient or others. It was also restated 
that only the researcher would have access to a portion of the recorded interviews, with 
her research supervisors having access to anonymised versions of a portion of the 
interviews for transcription purposes.  
 
Following data collection, all audio recordings of the interviews and interview 
transcripts were stored on password-protected computers located in the locked room of 
the researcher. A portion of the transcripts used for coding purposes was stored on 
password-protected computers by both supervisors in their locked rooms. No patient 
names were used during the interviews and any identifying information was removed 
from transcripts. The researcher used a code known nly to herself to identify 
transcripts. All documents pertaining to the study that contained identifying information 
were filed in a locked cabinet in the Clinical Psychology office at the hospital. Only the 
researcher and clinical supervisor had access to this. C ristians (2000, p.139) warns that 
watertight confidentiality may be an impossibility in that pseudonyms for research 
participants may be recognised by interested parties. Whilst pseudonyms were not used, 
the researcher made every effort to remove potentially dentifying features from 
participants’ quotations before their inclusion in the completed thesis. This will be the 
same procedure for anticipated presentations that are based on this thesis.  
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2.3.4 Managing Participants’ Potential Fatigue 
Once the researcher was satisfied that the participant was not currently experiencing a 
chest infection, each interview was preceded with the reminder that the interview could 
be stopped at any point should the participant becom  tired or wish to stop for any other 
reason. The interview could then be rescheduled if desired by the participant. 
Participants were also reminded that the interviews were not fixed in terms of duration 
but would not exceed one hour. This advice was included on the Patient Information 
Sheet. Whilst no participant requested that the intrview be stopped, the researcher 
closely observed participants’ energy levels and on one occasion enquired whether the 
participant was able to continue. Further, to minimse risks of potential fatigue, 
interviews were not scheduled for days when participants had Run-in study visits. None 
of the participants were currently involved in any other psychological research. 
Interviews were also conducted at a time and locatin that was convenient for 
participants, recognising the need to minimise additional disruption to work, education 
and free time.  
 
2.3.5 Managing Potential Distress of Participants 
The researcher had experience of working with the emotional distress of patients in her 
role as a trainee clinical psychologist. The researcher was also undertaking a year long 
specialist placement with adults with CF and had knowledge and practice of working 
with issues specific to the condition.  
 
Prior to interviews taking place, it was decided that the researcher would stop an 
interview should a patient become distressed. It would then be ascertained if the patient 
wished to continue with the interview. If the intervi w was continued with the patient 
continuing to be distressed, the researcher would discuss with them sources of support 
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including potential referral to their local CF psychology service. A system had been put 
in place where local CF psychologists were prepared to offer support and back up to 
any participants who needed it. This had been developed by the researcher in 
conjunction with her clinical supervisor and with other CF psychologists. One 
participant became distressed during the interview due to the start of the gene therapy 
trial having been delayed. However, she did not wish to be referred to psychology, 
preferring the support of her husband.  
  
 
2.3.6 Considering Potential Distress at Non-selection for the Gene Therapy Trial  
 
The researcher was aware of participants’ potential distress at the prospect of not being 
selected for the gene therapy trial. Whilst distress was not inevitable, it was decided 
that the participant be allowed to raise any issues relevant to this situation. The 
researcher monitored the effect of the interview on the participant and was vigilant to 
both verbal and non-verbal signals that indicated possible distress. In addition, Kvale 
and Brinkmann (2009) raise the dilemma of a potential quasi-therapeutic relationship 
developing in which participants may share information hat they retrospectively regret. 
Following Kvale and Brinkmann (2009), the researche was aware that sensitive issues 
could suddenly arise during interviews. In the event she did not want to disregard the 
participant’s privacy by inappropriately and unethically using a therapeutic approach. 
As above (See Section 2.3.5: Managing Potential Distres  of Participants), she offered 
to refer the participant to psychology services.  
 
 
2.3.7 Safety Issues Surrounding Home Visits 
Because interviews were scheduled at a time and place convenient to the participant, 
and reasonable to the researcher, five of the twelve participants requested a home visit 
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for the interviews. To ensure the researcher’s safety, the clinical team were consulted 
prior to any home visit to determine whether there would be any likely safety issues 
should a home visit be undertaken. The researcher also provided her clinical superviso 
with a schedule of home visits and telephoned her clinical supervisor following each 
visit. This was in order to confirm that the visit had gone safely and to alert her to any 
issues related to the visit.  
 
 
2.3.8 Ethical Approval 
Ethical approval was granted by local NHS Research nd Development Management 
who expressed their satisfaction with the study design on the 3rd December 2008, 
pending full ethical approval. Full ethical approval was granted on 16 January 2009 
following minor amendments. A copy of the approval letters can be found in Appendix 
7. Identifying details of the centre where the researcher was based have been removed 
but the original approval letters can be produced if required. 
 
2.4 Pilot Study 
 
Prior to recruitment letters being sent out, two pilot interviews were undertaken with 
two volunteers, neither of whom had CF and both of whom were physically well. One 
interviewee was in his sixties and employed in the mental health field and one was in 
her thirties and employed in education. These interviewees were asked to use role play 
since three of the interview questions presupposed that the respondent would have CF 
and was involved in the CF Run-in study. The researcher considered it ethically 
inappropriate to conduct a pilot interview with CF patients who were not recruited for 
the CF Run-in study since they would not have the possibility of being selected for the 
multi-dose gene therapy trial. Although the two interviewees did not have CF, the pilot 
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interviews offered useful preliminary insights into the interview process and into the 
development of the researcher-interviewee relationship and its influence upon what is 
said during the interview.  
 
The pilot interviews also afforded the researcher t opportunity to practise asking the 
questions and to be guided by the interviewees as to the pace of delivery. They also 
allowed the researcher to perceive individual differences in responding to the questions.  
 
The researcher practised using the digital voice recorder (Olympus VN-1000PC) 
intended for use in the interviews and its attendant computer software. She had the 
opportunity of doing some initial transcribing before recruitment took place. Whilst 
there may be a place for taking notes during interviews, using recording equipment 
enabled the researcher to engage with the interviewee. Furthermore, the researcher was 
not trained in shorthand. However, the researcher took notes shortly after interviews to 
record any information not captured on the audio recording e.g. before or after 
interview, body language etc. 
  
Whilst the researcher was not herself interviewed using the schedule, she considered 
her own responses to the questions prior to recruitmen . She found this process 
sensitised her as to how the questions could be perceiv d by interviewees. Because the 
researcher found that she required time to formulate responses to the questions, she 




2.5.1 Inclusion Criteria 
Inclusion and exclusion criteria were based upon those used in the CF Run-in study. 
The researcher included the additional criterion that participants should not be currently 
participating in any other research of a psychological nature. This was due to concerns 
that the participants could potentially be overburdened by too many research demands, 
exacerbated by the daily treatment burden that many CF patients experience. All 
participants on the CF Run-in study were fluent in English. The criteria were as follows: 
 
o Diagnosed with CF. 
o Aged 16 or above.  
o Participating in the CF Run-in study in Scotland. 
o Not currently taking part in any other psychological study.  
o Neither awaiting referral for a lung transplant nor having been referred for 
such. 
o Not having had a lung transplant. 
 
2.5.2 Exclusion Criteria 
The following exclusion criteria were used to ensure fitness for participation in the 
interview: 
o An increase in CF symptoms e.g. increased wheeze or breathlessness in the 
preceding two weeks before interview.  
o The use of extra antibiotics for the two weeks prior to interview.  
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2.5.3 Identifying Suitable Participants 
The Run-in study is a UK wide study with the two main bases being London and 
Edinburgh, with Edinburgh recruiting participants from Scotland and the North of 
England. This study is limited to those patients recruited via the Edinburgh site due to 
geographical considerations for the researcher. There was discussion with the 
Edinburgh-based CF Run-in team (which consisted of the research manager and two 
research fellows working with the Gene Therapy Consortium) about which CF Run-in 
participants would meet the criteria for the current study. Because of the research 
fellows’ concern not to jeopardise the continuation f three participants who were 
considering withdrawing from the Run-in, these patients were not invited to participate 
in the current study. It was ascertained that forty-two participants in the Run-in study 
met the study criteria.  
 
2.5.4 Recruiting Identified Participants 
The Run-in study research team thought that the initial approach to patients should be 
made through the principal investigator from the Run-in study. This was to help 
patients understand why they were being contacted about the current study and that the 
invitation to participate had the support of the Run-in study. Information about the 
study was given to the principal investigator, who jointly drafted the invitation letter 
with the researcher. However, the letter stressed that the researcher was not part of the 
Run-in study and that accepting the invitation to participate would not influence 
patients’ chances of selection for the gene therapy trial.  
 
The researcher sent out the invitation letter signed by the principal investigator to 39 
patients. The Patient Information Sheet was included with the letter. The remaining 
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three identified patients were scheduled to attend a study visit, where they received an 
envelope containing an invitation letter and Patient Information Sheet from the research 
fellows. Due to an initial low response rate, a repeat invitation letter and Patient 
Information Sheet were sent out at a later date in the study to those who had not 
responded by telephone or e-mail or by returning the response slip attached to the 
invitation letter.  
 
2.5.5 Researcher Contact with Consenting Participants 
All but one consenting participant returned the response slips. These were telephoned to 
arrange an appointment for an interview. Before an appointment was arranged, the 
researcher again outlined the nature of the study to which they had consented and 
answered any questions participants raised. The resea cher also checked whether they 
still wished to participate in the study. For the one participant who gave verbal consent 
by telephone, the researcher followed the same procedure.  
 
Appointments were arranged for dates that did not coincide with CF Run-in study visits 
and at times and locations that were convenient to the participants. As outlined earlier 
(See Section 2.3.7: Safety Issues Surrounding Home Visits), home visits were 
undertaken only after they were assessed as being safe. Participants were asked to 
contact the researcher should the interview appointme  prove not to be convenient for 
them. The researcher telephoned each consenting partici nt approximately two days 
prior to the interview both to confirm the time and place arranged and to check whether 




2.5.6 Notifying Medical Professionals About Recruitment 
The researcher sent a letter to the General Practitioners and Hospital Consultants of all 
consenting patients. This was to notify them that teir patients had given consent to 
undertake the current study. General Practitioners and Hospital Consultants were 
invited to contact the researcher should they have any questions regarding the research 
and what it entailed for their patient.  
 
2.5.7 Summary of Recruitment 
Altogether, forty-two CF Run-in participants were identified by the Edinburgh CF Run-
in research team as being potentially appropriate for the current study. An invitation 
letter and Patient Information Sheet were sent out by the researcher to thirty-nine 
patients. Three participants received an invitation letter and Patient Information Sheet 
given by the research fellows at their study visit because they were due to attend at the 
time the letters were being sent out. There were four participants who indicated via the 
response slip that they did not wish to participate and there was one query by telephone 
for further information which did not result in participation. Due to an initial slow 
response rate, the invitation letter and Patient Information Sheet were sent to those who 
had not already indicated any response. Twelve participants altogether were recruited 
by letter to the current study. The researcher telephoned each participant who had 
consented by response slip to arrange an interview. There was only one participant who 
telephoned to give verbal consent during which conversation the researcher and 
participant arranged an interview. The researcher sent a letter to the General 
Practitioners and Hospital Consultants of all consenting patients. All participants gave 
informed consent. No participants withdrew therefor twelve participants completed the 




2.6.1 Approach to Conducting a Semi-structured Interview 
The researcher’s epistemological assumptions about the ype of knowledge obtainable 
in a qualitative interview are partially captured in the belief that an interview is 
essentially “intersubjective interaction” (Kvale, 1996, p.66). As such, qualitative 
interviews are influenced by the viewpoint and the values of the investigator (Kvale & 
Brinkmann, 2009) and by the construction of meaning by both participant and 
interviewer. For example, participants can reformulate questions during the interview 
and then answer these, even though the interviewer’s questions should lead the 
interview more in order for it to be “successful” (Mishler, 1985, p.54). Through the 
process of reformulation, both interviewers and participants try to establish mutually 
understood meanings (Mishler, 1985).  
 
The actions and words of participants are located within a particular context. This is 
described as the context of other meanings, beliefs, values and practices that 
participants will hold (Kvale & Brinkmann, 2009). The researcher was aware that 
gender, class, age and race amongst other factors would be part of the personal and 
social context of the participants. The researcher also needed to maintain awareness of 
how she might also interact within the interview-participant relationship. The 
researcher tried as far as possible to minimise potntial structural power relationships 
(Burman, 1994). Mishler (1985, p. 126) suggests that participants be seen as research 
collaborators i.e. as full participants in the analysis and interpretation of data. The 
researcher sent the participants a copy of her proposed themes before the final write-up 
of the research so that amendments could be made if warranted (See Section 2.9.1: 
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Validity). Following Glaser and Strauss (1967), the researcher set out to inductively 
develop a theory grounded in the data from the interviews.  
 
2.6.2 Interview Procedure 
Prior to the interview commencing, the researcher briefed participants regarding the 
nature of the study. A Patient Information Sheet was also available should participants 
need to refer to this again. The researcher allowed opportunity for participants to raise 
any questions relating to the study. The consent form was then completed and 
countersigned by both participant and researcher. Participants were invited to inform 
the researcher if they became fatigued and wished to reschedule. The researcher 
referred again to the interviews being recorded andemphasised confidentiality and 
anonymity in connection with written transcripts and recordings. Indeed, although 
access to the audio files was protected, the research r made participants aware that she 
would not use their names during the interview as an extra precaution.  
 
Prior to the interview being conducted, the participant and the researcher did a very 
brief pilot recording on the digital voice recorder to ensure that the equipment was 
recording correctly. These pilot recordings were eras d following the interview. The 
researcher was aware of maintaining as relaxed an atmosphere as possible to put 
participants at their ease. Part of this process involved showing a genuine interest in the 
participant and in his or her responses and minimising discomfort when there was a 
perceived power differential e.g. when the participant assumed superior knowledge of 
gene therapy on the part of the researcher, the latt r stated that this was not the case. 
The timing in delivery of the questions was regulated so that the participant had time to 
respond to, or to query, what was being asked. The res arch interviews varied in length 
 49 
from twenty-two minutes and five seconds to fifty-five minutes and twenty-seven 
seconds with the average interview time being thirty-two minutes and twenty-nine 
seconds. 
 
In keeping with Kvale’s (1996) advice to debrief participants following interview, all 
participants except one were invited to comment on their experience of being 
interviewed and to ask questions about the interview process or the study. The one 
exception was an interview in which the participant became upset. The research 
interview was ended and the researcher created space to discuss the possibility of future 
support for the participant. This enabled the participant to step out of the interview 
process with dignity.  
 
The researcher outlined how she would disseminate findings and highlighted that she 
would be more than happy to meet again with the participants individually to discuss 
the findings or to discuss these by telephone or e-mail. Immediately following the 
interview, the researcher recorded her thoughts and feelings with reference to the 
interview in her reflective diary. She also recorded aspects of the methodology that she 
felt could be improved e.g. not asking one question immediately followed by another 
related question, thus allowing the participant space for reflection as suggested by 
Kvale & Brinkmann (2009).  
 
2.7 Data Management  
 
Following each interview, the researcher downloaded the audio file from the digital 
voice recorder onto a password protected computer. The file was then deleted from the 
digital recorder. Codes were used to identify the fil s and only the researcher had 
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access to the coding system. The interviews were then ranscribed verbatim, with any 
identifying features excised from the transcripts. The researcher then double-checked 
each transcript for accuracy by checking the text against the recorded interview.  
 
Transcripts were formatted with wide margins, which allowed initial coding on the left 
hand side and questions, memos and focused coding on the right hand side. Following 
Parker (2005), pauses were marked and the word “unclear” was used to mark sections 
that were difficult to understand.  
 
2.8 Stages of Analysis 
Qualitative analysis was carried out on data from the research interview transcripts, on 
notes in the researcher’s reflective diary and on memos. The researcher began the 
analysis whilst transcribing research interviews as she concurrently started to notice 
occurring themes. Formal analysis began with coding. This is a fundamental process in 
grounded theory during which one defines what is occurring in the data and is thereby 
guided in developing theoretical categories which enable a theoretical understanding of 
the process being investigated (e.g. Chamberlain, 1999; Charmaz, 1995). Charmaz 
(2006) directs the researcher to interpret participants’ tacit meanings within data. The 
researcher was guided in her approach to coding by using the guidelines of Strauss and 
Corbin (1998) and Charmaz (2006).  
 
2.8.1 Initial Coding  
Following Strauss and Corbin (1998), text was initially coded by the researcher line-by-
line and by hand. As recommended by Charmaz (2006), the researcher tried to 
understand participants’ views and actions from their perspective, paying close 
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attention to the context of the data and participants’ implicit meanings. Codes used the 
gerund form of the verb as much as possible to allow the process to emerge rather than 
being descriptive and to keep the analysis grounded in the data (Charmaz, 1995). The 
researcher also frequently used codes based on the words of participants themselves, 
although line-by-line coding helped the researcher not to become immersed in 
participants’ accounts but to break the data into codes critically and analytically. Initial 
codes were written in the left-hand margin of the page, with the right-hand margin 
being used for more frequent codes, areas of interest and observations for later 
development into memos (See below). The researcher constantly compared sections of 
data side-by-side within transcripts and between tra scripts. An example of initial 
coding is provided in Figure 1.2 and a detailed example is given in Appendix 8.  
 
 












Expecting a normal 
life for future 
generations 
 
Hopefully it will mean that people with CF 












Well, normal if terms of lifespan and you 








impact of having CF  
 
None of this happened to me but you do hear 
about people who have to put up with an 
awful lot.  
 
Participant experience of 
CF seems to differ between 
early and late diagnosis -




over her own 
understanding 
 
I don’t fully understand whether the gene 
therapy would only treat the breathing 
symptoms or whether it would treat other 
symptoms as well 
 
 
Full versus partial cure? 
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2.8.2 Qualitative Data Analysis using  Software Support 
Using Nvivo8 helped the researcher to become more immersed in the data. After initial 
coding by hand, the codes were entered into the software package NVivo 8 (QSR 
International Pty. Ltd., 1999-2009) to assist with qualitative analysis and to help to 
keep a record of analysis done. The software package provided a visual representation 
of the data entered. The researcher continued to make comparisons between instances 
of data and to develop categories and subcategories. Thi  was helped by using existing 
memos and by drafting new memos. The memos were nots f the researcher’s 
observations and interpretations whilst coding. An example of an early memo is in 
Figure 1.3 below: 
 
Participant 1 
Keeping one’s expectations realistic 
 
Extract: 
I try to keep people’s expectations realistic. I try to keep my own realistic not least because I 
may not be selected for the actual therapy itself…. so I’m quietly confident but if works out 
that’s absolutely super, you know. (lines 53-62) 
 
 
The participant expressed his ambition to be fitter and healthier by being on the gene therapy 
trial but recognised that he needs to be realistic about any personal outcome of the gene 
therapy trial. He is also actively trying to keep the expectations of others realistic. The 
participant identifies the possibility that he might not be selected for the gene therapy trial. He 
likes the odds of being selected and he is quietly confident of selection. However, he contrasts 
this with “but” i.e. if it works out, it will be “absolutely super.” There seems to be a process of 
pulling back from complete hope that the trial will be beneficial for him and yet the hope of 
success is strong.  
  
Figure  1.3: Memo: Keeping one’s expectations realistic 
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2.8.3 Focused Coding  
The researcher moved on to focused coding which involved selecting the most frequent 
initial codes to categorise data and using these cod s to compare and understand larger 
segments of data. This took the analysis onto a more theoretical level as the codes are 
more conceptual than line-by-line coding (Charmaz, 2006). The researcher used 
focused coding to further refine categories.  
 
2.8.4 Axial Coding 
The researcher used axial coding to reassemble data that were broken down into distinct 
pieces during initial coding. Through constant comparison between pieces of data, the 
researcher validated her comparisons thereby furthering her analysis (Strauss & Corbin, 
1998). The researcher brought the data back together by linking categories and 
subcategories and by specifying their dimensions and properties (Charmaz, 2006). 
Through this process, a large amount of data was organised and put together in a new 
way.  
 
2.8.5 Selective Coding 
In selective coding, the theory was integrated and refined as the researcher selected an 
emerging central concept that was able to draw all the other categories together. This 
created an overall explanatory concept of the process b ing studied (Strauss & Corbin, 
1998). Nvivo8 was used to draft models of the central concept and its relationship to 
other categories. Memos were used to build links betwe n categories and to develop the 




2.8.6 Theoretical Saturation 
The researcher was able to collect data until she was largely satisfied that no new 
properties of categories would arise, although fresh theoretical insights could still have 
occurred.  
 
2.8.7 Writing This Manuscript 
The researcher continued to undertake data analysis as she wrote this manuscript. This 
helped with the furtherance of insights, the development of new ideas and the creation 
of a theoretical framework to explain the researcher’s analysis (Charmaz, 2006). The 
researcher continued to develop her analysis by gaining further insights in writing 
several drafts of the manuscript.  
  
2.9 Warranting Quality in Qualitative Research 
The management of quality in qualitative research is a highly pertinent topic and 
consideration needs to be given as to how questions of credibility can be answered 
since there is debate whether qualitative methods can be assessed with the same 
evaluative criteria as quantitative methods e.g. reliability, validity and replicability 
(Dallos & Vetere, 2005; Flick, 2007). Nevertheless the following criteria can be found 









If qualitative research is to be conducted plausibly, the researcher must monitor how 
the research has been conducted and to challenge himself or herself in this (Tindall, 
1994). The researcher recognised that her interpretations of participants’ experiences 
would be influenced by her assumptions and should therefore be “open to challenge” 
(Dey, 1999, p.136). Regular joint meetings between th  researcher and her supervisors 
provided the opportunity for the researcher to evaluate her own influence in the 
construction of findings.  
 
Following Flick (1998), the researcher sought to ground her interpretations in 
participant accounts with quotations being incorporated into the results to show the 
source of the researcher’s interpretations. Contextual validity was also involved with 
the researcher checking with participants whether the research account was 
recognisable (Dallos & Vetere, 2005; Tindall, 1994). One response to date has been 




For Dey (1999), the value of a transparent process is implied when grounded theory 
does what it sets out to do i.e. when an account is grounded conceptually in the research 
data. The researcher kept a record of how interpretation was undertaken throughout the 
research process through the use of memos and written notes. This highlighted 
questions that the researcher asked of the data and llowed her to record her reflections 
and observations of the data and of the research process. The researcher noted decisions 
concerning the development of her ideas which enhanced transparency. Transcripts of 
research interviews and related memos will be made available for review upon request.  
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2.9.3 Reflexivity  
In using reflexivity, the process through which the researcher produces the report 
material and analysis is made explicit. The key position of the researcher is 
acknowledged in the construction of knowledge (Tindall, 1994). The value of 
reflexivity in qualitative research has been emphasised in enhancing validity (e.g. 
Charmaz, 2006; Parker, 1995; Willig, 2001). The inclusion of analysis in a research 
report allows readers to judge the content within “the context of the perspectives and 
assumptions by which it was shaped” (Marshall, 1986, p.195). The researcher’s 
analysis has been included in the Results and Discussion sections of this report.  
 
Tindall (1994) highlights the important of personal reflexivity in recognising how 
personal interests and values affect the research process. In keeping a reflective diary a 
record can be kept of how findings were interpreted an  how the researcher’s belief has 
influenced the research. An entry from the researcher’s reflective diary is provided 




Interview with Participant 12 
Location: Hospital room 
 
The participant seemed very relaxed. He came across as very articulate and had 
clearly done some thinking on gene therapy. It was a reflective process for him as he 
commented on the fact that the interview was offering him the chance to think about 
things. He realised that he hadn’t asked some questions which might have been of 
help, perhaps prompting him to go and ask the questions at a later stage once he knew 
whether he’d got on to the next stage of the trial. It was a very interesting interview 
for me. In a way it’s harder with someone who is articulate and bright because you 
can get sparked into a conversation of mutual interes  or value the way they say 
something though hopefully not to the exclusion of content!  
 
I deliberately tried not to say too much during theinterview and to ask questions 
rather than to summarise too much. Also to give him space to say more!  
 




Typically triangulation is the use of more than one m thod and/or researcher within the 
same study to counter any gaps that might arise if only one researcher and/or method is 
used (Denzin, 1989). In the current study, data was collected by the researcher using 
one method and from one source. Following Flick (2007), in order to reveal and 
minimise biases, investigator triangulation was used where the researcher and two 
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supervisors compared their interpretations of interview transcripts. The collective 
nature of this approach largely confirmed the researcher’s analyses and usefully served 
to extend and at times challenge the emerging analysis. Therefore the use of 
triangulation acted as an important check on the dev lopment of analysis.  
 
 
2.10 Disseminating Research Findings  
 
Due to the risk of airborne bacterial and viral cross-infection between CF patients, 
results could not be disseminated to the participants via a group meeting. The 
researcher sent all participants a results summary (see Appendix 9). Participants were 
invited to discuss the results with the researcher in person or by telephone or e-mail.  
 
The findings will be presented to the Gene Therapy Consortium clinical research team 
members and results will also be made available to other Gene Therapy Consortium 
clinical research teams in the U.K. and to relevant CF health care professionals. The 
main findings will be submitted for peer reviewed publication. 
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3  Results 
 
In this chapter, the participants and the duration of the interview period are described. 
Qualitative findings from the interviews are also presented and these will be considered 
in further detail in the Discussion chapter.  
 
3.1 Participant Information 
 
Twelve participants took part in the study, seven bing male and five being female. The 
age range was from 19 to 53 years (mean 31.67; SD 10.07). The length of time from 
Run-in Study Visit One to the interview for this study ranged from 295 to 390 days 
(mean 347; SD 33.69).  
 
The age at which participants were diagnosed with CF ranged from birth to 48 years 
(mean 13.83; SD 17.13) with the time since diagnosis to the time of interview ranging 
from 3 to 38 years (mean 17.83; SD 10.33).  
 
The researcher had supervised access to the particints’ Forced Expiratory Volume 
(FEV1) % predicted scores as recorded in the Run-in Study Visit One. FEV1% 
predicted is a percentage measurement of the lung fction that is expected for 
someone without CF of the same age, height, weight and gender and is used as a guide 
to the severity of CF. It was suggested in personal communication with Dr. J. Alastair 
Innes, lead consultant physician for CF for the Scottish Adult CF Service, that CF 
severity be ranked in terms of low lung function (moderate range) and high lung 
function (mild range). No participants were in the severe range of CF, as they did not 
meet the criteria for the Run-in study.  
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Of the participants, six were in the mild range of CF and six were in the moderate range. 
For the former, lung function was within non-CF normal range and their quality of life 
was largely not affected by CF. For those in the moderate range, there was some impact 
of CF upon lung function and upon quality of life. There were four participants who 
had been diagnosed with CF as adults, three of whom were in the mild range and one of 
whom was in the moderate range. Participant details are presented in Table 1 below. 
 














Number of years since diagnosis  
0 – 5 3 
6 - 10 0 
11 - 19 4 
20 - 29 3 
30 - 39 2 
FEV1% predicted   
Low lung function (moderate range)  
45- 78% predicted 6 
High lung function (mild range)  
79 – 120 % predicted  6  
Time Between Study Visit One & Interview  
9-10 months 3 
10-11 months 2 
11-12 months 2 
12-13 months 5 
Marital Status  
Single 7 
Married/with partner 5 
Highest Level of Education  
Secondary School  1 
Tertiary Education (including those currently studying) 
 
9 
Vocational training 2 
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3.2 Duration of Participation 
Each interview was completed within a single visit. The length of interview ranged 
from 22.1 to 55.5 minutes (mean 32.2; SD 8.6). Interviews three to eleven included 
participants’ thoughts on the interview process. Interviews one and two did not have 
this recorded (See Section 4.4: Researcher’s Reflections on the Interview Process).  
 
3.3 Qualitative Findings  
 
3.3.1 Overview of Participants’ Expectations of Gene Therapy  
The main aims of the study were to discover the expectations that participants recruited 
in Scotland and Northern England for the CF Run-in study had of the gene therapy trial 
and of gene therapy in general. It was also to ascertain whether these expectations 
changed during their participation in the CF Run-in study. The main aims included 
whether participants had any misconceptions about gene therapy. Difficulties and 
benefits of participation in the Run-in study were also explored.  
 
“Expectations” and “Managing Expectations” were the core categories identified 
through analysis of the participants’ interviews. These are detailed through the 
suggested dynamic relationships between the subcategories “Hoping gene therapy 
works” and “Strategies for managing expectations” and the major sub-theme “Trusting 
in the system” (i.e. participants’ expectations of gene therapy from the trial and in the 
future were managed by the use of individual coping strategies and by ongoing trust in 
the research team and local CF teams). There was an overlap between participants 
hoping that the treatment would work for them and hoping that it would work for others. 







Figure 3.1: Dynamic Relationships between Core Categories and Subcategories 
 
The core categories and subcategories will be discussed in turn, with the sub-categories 
being described through their respective sub-themes. Each will be supported by quotes 
from participants’ transcripts in order to show the underlying data. Quotes for both 
researcher and participant are presented in italic font, with the researcher’s being in 
bold font.  
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3.3.1.1 Core category: Expectations of gene therapy  
This category describes the expectations participants have of the gene therapy trial and 
of gene therapy for CF. The core category “Expectations of gene therapy” is described 
through the following subcategory and its respectiv sub-themes:  
 
o Subcategory: Hoping gene therapy treatment works  
o Sub-theme: Hoping gene therapy works for me 
o Sub-theme: Hoping to participate in the trial. 
 
Initial comment on “hope” and “expect” 
“Hope” and “expect” were frequently used by participants to describe their expectations 
of the gene therapy trial. Both of these terms were oft n used synonymously and 
therefore could overlap and work in a dynamic relationship with each other. The 
researcher tried as far as possible to understand what the participant meant in personal 
usage of these terms, one example being: 
 
So I’d hope, you’d hope but I don’t know if you can maybe expect it to be clear cut the 
first time round.  
And what would you say’s the difference between hope and expect for you? 
You’re not wanting to get any worse, you’re going to hope that it does work but at the 
same time you’re old enough to realise that things don’t always run smoothly. I’m not 
saying I’d expect it to necessarily work first time but I’d say that’s what I mean by I’d 
hope it would work. (Participant 7, excerpts from lines 238-281).  
 
 
The main difference between the two terms is that “ope” was used in a much more 
general sense as an expression of wishing for particular outcomes without assessing the 
likelihood of how such outcomes could be achieved. “Expect” had a much higher 
component of realistic assessment of the likely outc me and seemed to apply to more 
concrete and personal expectation. The researcher considered that for some participants, 
taking part in the Run-in study moved some “hope” into the category of “expect.” 
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Therefore by participating in the Run-in Study, participants acknowledged that they 
were a step closer to hopes becoming expectations. To what extent this happened and 
whether participants’ expectations were realistic will be explored. 
 
Subcategory: Hoping gene therapy treatment works 
Of the twelve participants, eight explicitly used the word “hope” in regards to wanting 
the gene therapy trial to work. The remaining four pa ticipants implicitly showed hope 
of the trial being successful in wishing for clinical benefits from it for themselves, 
although one mainly hoped for benefits for future generations.   
 
The subcategory “Hoping gene therapy treatment works” is further described through 
the following components, with analysis being drawn from the researcher’s own 
memos:  
o Hoping gene therapy works for me 
o Hoping to participate in the trial 
 
Sub-theme: Hoping gene therapy works for me 
The researcher found that ten of the twelve participants hoped that the gene therapy 
trial would have some clinical benefit for them. Four f these participants said that they 
did not have any expectations or did not know what to expect. The remaining two 
participants said that they did not expect personal benefit but still expressed the hope 
that the trial would work for those known to them or those in the future.  
 
Even though the magnitude of clinical benefit anticipated from the gene therapy trial is 
unknown, there was still a range of personal hopes expressed regarding clinical benefit 
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from the trial. Based on the researcher’s analysis (Memo 43), the hope of personal gain 
was not always influenced by CF severity.  Participants with both mild and moderate 
CF hoped that medication would be reduced or no longer required. In the two examples 
below, the first participant in the mild range showed that she would like to be free from 
all the “little silly things” that go along with CF and the second in the moderate range 
that she would like to be free from the burden of treatment:  
 
Well, I’m quite healthy anyway so it probably would be all the little silly things that go 
along with it [CF] like not needing to take Creon [enzyme replacement] anymore or 
something like that. Being able to kind of to cope, my body to cope with that on its own 
instead of on medication. (Participant 4, lines 244-250) 
 
a life without having to think, “Oh I’ve got to rush and go and get the, go home and 
nebulise [inhale medication] and go and do physio and…,” just a bit free with time and 
life. (Participant 6, lines 457-461) 
 
Whilst it may be that the burden of treatment will be reduced for those in the future, 
hopes of this from this trial were not likely to bemet. In addition, the first participant 
hoped that gene therapy would remove general symptos of CF whereas the lungs are 
the target of gene therapy for CF and likely to remain the only target (J.A. Innes, 
personal communication, 24 June 2009). This highlighted that participants may not be 
entirely aware of the intended research aims of gene therapy treatment. In the 
researcher’s analysis (Memo 48), misconceptions seemed less likely to arise when 
participants moved from hope to expectation, althoug  this process did not seem to 
have yet happened for the participant in the mild range with hope being in the 
ascendancy:  
 
Again I suppose I would always hope for something positive to come from it but I don’t 




Regardless of disease severity, participants hoped that lung deterioration would be 
halted or at least slowed down. A respective example of this from the mild and the 
moderate range is as follows:  
 
[gene therapy] would kind of  keep my lungs in stasi , so as they are now, it would stop 
the progression of the lungs getting worse and it would just, this would be my level. 
Which is obviously fantastic… (Participant 8, lines 15-20) 
 
It’ll be a great help for everybody with CF, keep you sort of steady at the same level. 
You hope you won’t get any worse. (Participant 7, lines 17-20).  
 
 
The researcher considered whether the participants’ experience of peers in the CF 
community becoming progressively worse or dying was influencing their expectations 
of personal benefit from the trial. It was unclear whether the first participant knew that 
current lung function is the best predictor of future health (J.A. Innes, personal 
communication, 24 June 2009), but it was clear thatwith lung function in the normal 
range she still hoped that gene therapy treatment could deliver guaranteed lung stability. 
Whilst this was an understandable hope, it was unlikely to be the outcome of the 
immediate gene therapy trial since it is largely designed to measure clinical benefit.  
 
However, misconceptions could also be recognised and challenged. The participant 
herself corrected her own understanding by bringing it to a more realistic level. She 
anticipated that a successful outcome would take at l ast ten years and asked whether 
she would be well enough to benefit from treatment at that time. Yet she was still able 
to hope for immediate benefit for herself, demonstrating how a participant’s optimism 
can exist alongside realistic appraisals.  
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Indeed, the researcher’s analysis indicated that hope was not always tempered by 
external reality (Memo 2). When participant knowledg  of the success and limits of 
gene therapy in general was evident, this did not necessarily preclude hope that the 
symptoms of CF and their consequences would be remov d. One participant in the mild 
range had read the Run-in patient information sheet and had some knowledge of the 
uncertainty of human trials, yet still wished for the following: 
 
[the success of the gene therapy trial would] just mean that I can lead an active normal 
life without having that nagging doubt in the back of your head all the time, “What if?” 




This level of hope was similar to that of a participant in the moderate range who had a 
self-confessed lack of knowledge of the Run-in study and of gene therapy in general: 
 
I just wouldn’t have that cloud over my head saying I’ve got CF all the time. I’d just be 
free. (Participant 5, lines 502-504) 
 
This raised the question as to how hope and expectation worked together in a dynamic 
relationship since hope was present regardless of level of knowledge. The hope 
expressed by the first participant did not seem to be tempered by his awareness that the 
multi-dose gene therapy may not work first time round: 
 
If I was selected, again the outcome of the trial… there’s what I’d like to happen 
obviously which is it works, on your current treatment for the rest of your life, happy 
days. I think it’s really hard to have any expectations until as I said you know roughly 
what’s going to happen with it. (Participant 12, lines 365-372) 
  
 
It would appear that participants could be well informed and yet choose to hope rather 
than expect more realistic outcomes from the trial.  
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Sub-theme: Hoping to participate in the trial 
In this sub-theme, the hope of participation is in a dynamic relationship with the hope 
of receiving active treatment and the level of expectation of potential benefit from the 
trial.  
 
Overall, eleven out of twelve participants explicity expressed the hope of being 
selected to participate in the gene therapy trial. This consisted of all six participants in 
the moderate range and five participants in the mild range. Although willing to 
participate, the remaining participant who had been diagnosed with CF as an adult did 
not expect to be selected based on the Run-in criteria b cause he believed himself too 
healthy for the gene therapy dose: 
 
They wouldn’t see much of an improvement by giving me gene therapy (Participant 2, 
lines 376-377).  
 
Of the participants, all six in the moderate range expressed the hope of being selected 
for active treatment on the gene therapy trial, although they were also willing to be 
controls. With participants in the mild range, three out of five explicitly hoped for 
active treatment, with two implicitly indicating this. As above, the remaining 
participant was willing to have active treatment budid not expect it. However, he 
along with four other participants in the mild range explicitly said they were willing to 
be in the control condition. Only one participant i the mild range, who was diagnosed 
late with CF, said he would be “a bit disappointed” not to be receiving active treatment 
albeit he recognised the placebo was necessary to the trial (Participant 1, line 502).  
 
The researcher’s analysis (Memos 9 & 38) of the difference in hope and expectation 
between the two participants above with late diagnosis indicated that the extent to 
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which a person had adjusted to having CF may have influenced their approach to the 
trial. Participant 2 who was also in the mild range had had over ten years to adjust to 
diagnosis whereas Participant 1 was still coming to terms with his diagnosis as it was 
“rather fresh and actually rather raw” (line 446). Further, Participant 2 described less 
CF symptoms than Participant 1 and appeared to haveless personal investment in 
participating in the trial, his main motivation being to help a family member with 
moderate CF.  
 
Participant 1’s potential sense of disappointment about the possibility of not being 
given active treatment was also expressed by other participants:  
 
I think it’s a great thing like when I first heard about it, it was like, I can’t believe it! 
It’s [going to] be so good. I’ll probably be disappointed about not being able to be part 
of that. (Participant 4, lines 323-327) 
 
I’d probably be a bit disappointed if I wasn’t invol ed in the actual gene therapies part 
of it… it would be a shame to get to that point, which is kind of make or break and I 
wasn’t chosen to be part of the next part of it because it’s been interesting you know. 
(Participant 11, lines 296-303) 
 
Whilst the possibility of not being selected for active treatment was anticipated, with 
one participant predicting that it would be “devastating” (Participant 4, line 524), there 
was evidence that she had not anticipated this in any detail (Memo 1). During the 
interview, the same participant actively thought through the process of how she was 
likely to experience being disappointed, imagining it as a short-term experience:  
 
I’d  probably think about it quite a lot, but really the same as everything else, you start 
to think about it less as the days go on. It’ll probably be okay I think. So I’ll say that 
now though. I don’t know. (Participant 4, lines 334- 39) 
 
This response showed the similar difficulty of accurately predicting a response to not 
being selected for the trial itself as opposed to being selected for the active treatment. 
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Indeed the participant indicated that she was thinking about selection “quite a lot” (line 
343).  
 
This raised the question of how participants would adjust to not being selected for the 
gene therapy trial. Whilst there was not sufficient vidence to suggest that there would 
be difficulties for every participant if not selectd, there was a sense of the unknown in 
how participants would react, and a strong sense of hopes potentially being dashed if 
the trial were not successful.  
 
Despite participants actively managing expectations of the trial, several participants had 
invested significant hope in the trial. As described by one participant, this was perhaps 
because there was the “chance that it would work” (Participant 7, line 316). Indeed, 
one participant who had recently received a letter informing her of a delay to the gene 
therapy trial became so upset at the thought of not being potentially well enough for 
eventual selection that the interview had to be prematurely closed. In the researcher’s 
analysis (Memo 48), this participant was one of twoho appeared anxious to benefit 
from active treatment on the trial. As one was in the mild and one was in the moderate 
range, anxiety was not indicative of disease severity. However, both had been 
diagnosed as adults with CF within the past five years and, as indicated above, there 
may still have been adjustment to the implications f having a diagnosis of CF.   
 
3.3.1.2 Core Category: Managing Expectations 
This category describes not only the expectations participants have of the gene therapy 
trial and gene therapy in the future but also the srategies they are utilising to be able to 
manage and continuously refine these expectations. This is particularly relevant 
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because at the current time, not only is the participants’ selection and thus participation 
in the gene therapy trial unknown, but the actual otc me of the gene therapy treatment 
for people with CF is unclear. 
 
The core category “Managing expectations” is described through the following 
subcategory and its respective sub-themes:  
 
o Subcategory: Strategies for managing expectations 
o Sub-theme: Not raising hopes 
o Sub-theme: Not thinking too far ahead 
o Sub-theme: Trusting in the system  
o Trusting the gene therapy product 
o Trusting the research team and the information theyprovide 
o Trusting local CF teams and the CF Trust 
o Sub-theme: Hoping gene therapy works for others in the future 
 
Subcategory: Strategies for Managing Expectations 
Sub-theme: Not raising hopes  
Not raising hopes was a strategy that five participants used to safeguard themselves 
against being disappointed if the trial proved not to be clinically successful (Memo 39). 
For example, one participant was expecting there to be challenges in the development 
of a gene therapy product: 
 
There’s always a bit of trial and error and so obviously you’d hope that it would work, 
but maybe part of me at the same time expects it probably wouldn’t first time round or 
maybe not as so smoothly next time. (Participant 7, lines 228-234) 
 
Participants were also using a thinking style conducive to keeping hopes in check. As 
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reflected in one of the researcher’s memos (Memo 31), one participant demonstrated 
how she was actively avoiding thoughts of a successful clinical outcome from the trial, 
preferring this to come instead as a “great surprise” (Participant 11, lines 148-149). 
Hopes were implicit, perhaps even for the participant, with her wanting to hope but 
controlling the hope in order to avoid disappointment. This possibly stemmed from her 
realistic expectations of the trial:  
 
I don’t expect it to make much of a difference to me as I don’t think it will be in my 
lifetime that it’ll cure or anything like that. (Participant 11, 115-118).  
 
Another participant was deliberately not thinking about the Run-in but going about his 
everyday life as usual:  
 
I’m not getting my hopes up, just take it as it comes.  
So how much are you thinking about it in-between times? 
I’m not thinking about it. Just going in and doing the tests and that’s it. ……I just get 
on with my life and just that’s it, just take each day as it comes. (Participant 10, lines 
281-296) 
 
In addition, the researcher’s analysis (Memo 39) indicated that participants used 
specific criteria whereby they could avoid raising their hopes until they could be more 
certain of a positive outcome. To illustrate this, one participant realised that she could 
ask for further information about the gene therapy trial before it started but was 
reluctant to do so. Her response implied her assumption that the information given 
would be positive therefore asking might engender false hope:  
 
So what would happen if you asked for information now, compared to waiting till 
later? 
I suppose I could really, but I wouldn’t like to get my hopes up and get all excited and 
then find out maybe it doesn’t, there isn’t enough money, maybe it’s not going to be 
continued. (Participant 6, lines 166-173) 
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This was in contrast to Participant 12 (See Sub-category: Hoping gene therapy works 
for me), who eagerly sought information. Regardless of whether participants sought or 
avoided information, they still seemed to value hope as a coping mechanism.  
 
Sub-theme: Not thinking too far ahead 
There was evidence of four participants using the srategy of not thinking too far ahead 
in order to keep expectations realistic. A participant in the high lung function range set 
the criterion of “wait and see” to regulate expectations, saying his expectations of gene 
therapy would change if there were a viable gene therapy product available:  
 
If there’s something in front of me and it works, great. If there isn’t, well there isn’t, it’s 




However, one participant in the low lung function range went even further in not 
allowing himself to expect that gene therapy treatment would work until he had first 
seen proof of this:  
 
My views will probably change once the gene therapy does come in and helps 
everybody and I’ll probably see things different buup until then I’ll just see the way I 
see things. (Participant 10, lines 88-92) 
 
In the researcher’s analysis (Memo 41), some participants experienced the process of 
managing expectations within the personal context of living life for now and not 
dwelling on the future possibility of gene therapy. This was shown in the following 
example of a participant who realistically explained that he might not be selected for 
the gene therapy trial, and indeed had not considered if the active treatment would be 
successful: 
 
I don’t really tend to consider it much. … I’d rather just keep on living instead to the 
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full just now, just cross the bridge when it comes to it. (Participant 7, lines 731-736) 
 
 
It is common for people with CF to live life to the full without thinking of the future 
ramifications of the disease and the researcher wondered whether this influenced the 
reluctance to think about the possibilities of benefit from gene therapy treatment. It was 
likely that the participant was managing the uncertainty of the outcome of the trial in 
the same way as he managed the uncertainty of whether his lung function would remain 
stable i.e. by not thinking too far ahead.    
 
However, a contrasting example was shown in the appro ch of one participant who had 
inadvertently believed that he was being offered gene therapy treatment immediately. 
Perhaps because he had been in a position when he had believed the trial to be 
imminent, he was able to think ahead to its eventuality in the hope that it would make 
him physically “better, fitter and healthier” (Participant 1, line 48). Within this process, 
he too was aware that he might not be accepted for the trial and therefore qualified his 
future expectations:  
 
I try to keep people’s expectations realistic. I try to keep my own realistic. (Participant 
1, lines 53-55) 
 
 
Although the participant did not express how he wastrying to keep the expectations of 
others realistic, he stated for himself that he would grasp “with both hands” (line 275) 
the opportunity even to be two percent better due to receiving active treatment. The 
researcher considered that there was some evidence of th tension between thinking of 
the future clinical benefits of the trial and yet trying to keep his expectations realistic 
(Memo 2).  
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Sub-theme: Trusting in the system 
The issue of patient trust in the medical system is crucial. Without trust, patients find it 
harder to work with clinical teams to maximise medical care and to manage and, at 
times, adjust their expectations of their disease. This sub-theme explores the important 
question of when and how participants in the trial used trust in the medical and wider 
CF system to manage their expectations. The following three aspects are considered 
within this sub-theme: 
 
o Trusting the gene therapy product 
o Trusting the research team and the information theyprovide 
o Trusting local CF teams and the CF Trust 
 
Trusting the gene therapy product 
Participants’ trust in the gene therapy product increased as a result of the growing 
realisation that an important national study was taking place. This was reinforced after 
the required visit to Southampton for a three-dimensio al lung scan as part of the Run-
in study. Nine participants appreciated the visit with three not mentioning the benefits 
of it. The researcher’s memo (33) indicated that because of the visit to Southampton, 
participants became aware of the researchers doing something bigger and more real 
than they had first thought. One participant summed this up succinctly:  
 
I think I feel more positive about it. I think beforehand it seemed a little bit sci-fi… And 
I think now it feels a bit more real. (Participant 3, lines 529-533) 
 
Indeed, over the course of the Run-in study six participants saw their expectations of 
gene therapy increasing, three being in the mild and moderate range respectively. This 
increase was because the Run-in study was already hppening, making it easier to 
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expect that gene therapy treatment would now be devloped and become an even more 
effective treatment in the future.  
 
In the context of people with CF having lived with the hope of gene therapy treatment 
for two decades, one participant in the mild range indicated that the period of waiting 
was now drawing to a close. She moved from a position of frustrated hope: 
 
Is it really going happen, we’ve been talking about this for such a long time? 
(Participant 8, 949-951) 
 
 
to an expectation that an effective product was now g ing to be developed, though 
having recently attended lectures on gene therapy she expected that it would not be for 
five to ten years: 
 
It is within our grasp. That they are starting to dlike single dose trials, and just with 
having the Run-in study take place it’s like that, “Okay, you know we’re off the starting 
block. (Participant 8, 955-960) 
 
 
The three participants in the moderate range also saw gene therapy treatment as 
something much more possible, examples of this being:  
 
[Expectations are] much higher…Just because I didn’t k ow they were doing it back 
then and now I know what they’re trying to do. (Participant 5, lines 483-488) 
 
It’s just more real….. I’d just always heard about it and talked about it and read about 
it that this is actually happening. (Participant 6, lines 483-486) 
 
Given that six Run-in participants’ expectations of the gene therapy product had 
increased even without participating on the gene therapy trial, the researcher considered 
that expectations would be higher when participants were in a position to potentially be 
receiving active treatment on the trial (Memo 46). 
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Of the six participants who had seen no change in expectation, one participant from the 
mild and one from the moderate range respectively said that this was because there had 
been no increase in their knowledge. One participant e ch from both ranges said that 
they had had no expectations to begin with and had not developed any over the course 
of the Run-in. However, throughout the Run-in, one of these participants anticipated 
that participation in the trial could be something “very big” (line 88, Participant 11) if 
it were successful and became more eager to participate because of its importance. One 
participant from each range required to see the finished product in action in order to 
amend their expectations as to its effectiveness.  
 
Although two participants had the benefit of a scientific background in understanding 
gene therapy in general, no participant expressed confidence in fully understanding the 
gene therapy treatment in the forthcoming trial. The overall level of knowledge 
indicated that participants were less likely to understand the gene therapy product. 
Despite this, twelve participants were willing to receive active treatment though with 
the following different perspectives.  
 
There was evidence of participants not seeing the need to understand the science behind 
the gene therapy product in order to have faith in it, thereby trusting the research 
system that had developed it and being confident in their expectations of it being safe 
enough to use: 
 
To be perfectly honest I don’t even know how the drugs I’m on work so assuming that 
they work. I’m not really going to be so bothered about the whats, the whys, and ifs and 
hows in particular... (Participant 1, lines 35-40) 
 
 
Yet one participant appreciated that concern about a gene therapy trial was warranted. 
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She based her confidence in the product on reasoning that the gene therapy product 
would be safe enough to use by the time of the gene therapy trial, expecting that it 
would have previously been tested on others in the single dose safety trial:  
 
I suppose with any medical trial you have to be nervous about taking something into 
your body that hasn’t been, you know, has only been tri d on a few people and whether 
it will have any really bad effects, but I think I’d be reasonably confident that it had 





Four other participants expected a stage-based developm nt of the product, one of 
whom anticipated that the gene therapy product might not initially work:  
 
You know, it might happen that nothing, it actually doesn’t work given that they’re 




However, he anticipated that it would be a viable product and therefore worthy of trust, 
expressing the hope that it might be ready relatively soon: 
 
It might be a human trial in ten years but it’s been done in mice and proved successful 
and saying, “Now it’s like we’re actually doing it humans now” so it might be in your 
very near future. (Participant 12, lines 782-787) 
 
The researcher’s analysis (Memo 15) suggested that this participant’s citing of the 
previous success of gene therapy for CF in mice made the gene therapy product for 
humans seem more likely, even though it has proved difficult to replicate the disease in 
the lungs of animals. Therefore it is likely that there was a leap of faith in the belief that 
the product would be in the “very near future” and this is perhaps why the participant 
spoke of this in tentative terms by using “might.” However, this may also have been a 




Another participant described the development of a “safe” product, which would then 
be superceded by a more effective treatment: 
 
And then the second lot of research that will kind of continue on after that [the “safe” 
product], will be the big “Wow.” You know, you maybe only have to take it very, very 
occasionally, and it will be amazing. (Participant 8, lines 117-121) 
 
The participant appeared to trust that the “safe product” would indeed be safe. Despite 
being well informed of the trial to date, she offered no description of the risks that 
could be involved in a potentially dangerous procedur . The researcher wondered 
whether this indicated the level of trust the participant had in the research team such 
that she was able to expect a safe product. 
 
Trusting the research team and the information they provide. 
Trust in the research team was demonstrated with regard to many areas of their work, 
which included trust in the selection criteria for the trial, overall trust in the trial and 
trust in the information provided by the research team.  
 
Participant’s trust in the research team using expert criteria for selecting participants for 
the gene therapy trial was exemplified in the following statement by a participant in the 
moderate range:  
 
If you don’t meet the criteria then you obviously can’t be selected. It’s not something 
you can go and cry about. It’s just they’re the experts. They know what they’re looking 
for. (Participant 7, lines 758-762) 
 
 
This trust in the selection process applied not only for the Run-in Study but also for the 
main gene therapy trial. Whilst not being selected would be disappointing, the above 
participant’s trust was such that he expected the res arch team would make the right 
decision, thereby removing any sense of personal responsibility for him to be as ready 
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as possible in order to be selected (Memo 29). Thiscontrasted with another participant 
in the moderate range who took on the responsibility to stay as fit as possible in order to 
be selected: 
 
I just need to get healthy, stay healthy, when I come back, do very good and hopefully 




One factor that seemed to help participants to trust he research team was a belief in the 
skill of team members and their approach towards the research. For example, one 
participant commented that the research team was professional and that this had 
enhanced her trust in them: 
 
They’re clearly very professional and I’m sure they’r  extremely good at their jobs 
(Participant 3, 498-450) 
 
 
However, the same participant had initially wondere about the seriousness of the 
research team due to the adoption of a casual approch. This seemed to indicate that 
trust in the research team was a developing process (Memo 47). 
 
The trust that participants had in the research team w s also illustrated by the fact that 
they felt that the research team would continue to undertake research even beyond their 
participation. This would help others known to the participants. For example, a 
participant in the mild range was taking part for the future benefit of a family member 
but whilst not personally investing in the outcome of the trial, trust was still required in 
the research team to make the best use of his contribution to the research effort: 
 
My contribution is a little cog in a big machine, you know that the actual system is 
taking care of my contributions without me having to personally have to do too much. 
(Participant 2, lines 506-510) 
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Only two participants had sought information about the gene therapy trial from the 
research team. Three of the remaining ten participants expressed confidence in the team 
being able to deal well with their enquiries, two examples of this being: 
 
I’m sure they [research team] would clarify it more like if I was selected, actually let 
me know what was going to happen, it’s just not really been talked about really yet. 
(Participant 4, lines 186-189) 
 
I’m sure if I discussed it with any of the team I’msure they’d be happy to talk until the 
cows come home about it, but I never have. (Participant 3, lines 44-46) 
 
 
The latter also indicated that she would believe implicitly in any information from the 
research team: 
 
I think anything that came from the team in writing or them telling me it I would believe 
it just automatically. (Participant 3, lines 54-57) 
 
 
Of the seven participants who had not sought any information about the gene therapy 
trial, five did not feel the need to do so. The reasons given were various. One 
participant said that he was not the sort of person to ask for information, one was more 
interested in asking questions on current health statu  and one cited general knowledge 
about gene therapy from media sources. Another participant was contributing to 
research for the benefit of others and one said she had enough knowledge about gene 
therapy but felt that there had not been clear communication about the Run-in study, 
albeit she had not asked any questions of the research team.  
 
In contrast, the two remaining participants were planning to ask the research team for 
information, one wishing to wait until selection for the gene therapy trial and one 
having recognised during the interview for the current study that he should ask for 
information as he did not know anything about the trial. The researcher’s analysis 
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(Memo 6) indicated that for this participant, and for one of those who did not feel the 
need to ask for information, respective parents had actively been obtaining information 
about gene therapy albeit not about the trial itself. It was likely that in these cases, not 
asking for information did not indicate lack of trust in the team but continued trust in 
parental support, which is a frequent feature of young adults with CF.  
 
 
There was also evidence of two participants believing information from the medical 
research fellows in the research team because of their privileged position regarding 
knowledge. Whilst one participant appreciated the frank approach of the doctors, the 
other participant felt that his questions asking for specific outcomes of the trial could 
not be answered: 
 
The doctors should know more than anyone else so I prefer to talk to them and believe 
the information that they tell me and the doctors are very forthcoming with information 
and they don’t try and make it all flowery and rosy or anything like that. (Participant 9, 
lines 38-46) 
 
They might not be the right questions [he has asked th  research team] to be honest 
with you. There’s just nothing clear about what’s going to be the future after the gene 
Run-in. (Participant 12, lines 307-310) 
 
The comments of the second participant drew attention to the fact that this type of 
research cannot be trialled in animals since it is a human disease which has not yet been 
fully replicated in animals. Yet the participant still commented that information from 
the research team was “not freely given out” (lines 314-315).  
 
It was possible that the second participant above may not have had full trust in the 
research team’s communication with him, resulting i h m feeling less supported in 
managing his expectations since he did not receive answers that would have been of 
help. However, he concluded that lack of information was perhaps “just cos we don’t 
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know” (lines 317-318), recognising the uncertainty of human trials such as this one. 
The researcher’s analysis indicated that two separate but linked processes were 
happening: the research team itself could not guarantee the outcome and the participant 
was experiencing the uncertainty of not knowing the personal outcome of the trial and 
of not having this uncertainty addressed (Memo 7).  
 
 
Participants felt that the research team were generally interested in their ongoing 
research care and were friendly. Evidence of this wa being given clinical benefits such 
as medical advice and being helped with symptom management. There were four 
participants who experienced clinical benefits, two of whom had been diagnosed in 
adulthood. An example of experiencing benefits is as follows: 
 
I’m aware that I’m in probably better shape now and I know that I’m perhaps sort of 
stable between visits so the gene therapy Run-in study just gives me a bit of back up. 





Trusting local CF teams and the CF Trust 
Five out of the twelve participants showed evidence of trust in their local CF teams 
during their participation in the Run-in study (Memo 17). The advice of a medical 
consultant was called upon when one participant in he mild range expressed the 
following disappointment about not being able to keep receiving the gene therapy 
product if the trial were successful:  
 
If you do get taken to take part in the gene therapy study, and you feel better for it after 
a year, and then you come off it again. You don’t want to not be in it, but on the other 
hand, to know what’s going to be great, and then not have it after that, go back to 
normal life, but, however, however. (Participant 8, lines 151-159) 
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The participant felt reassured by her medical consultant saying that the trial would be 
more about tracking changes than about giving clinical benefit. The participant’s sense 
of reassurance indicated that trust could be maintained in clinical teams responsible for 
participants’ ongoing physical care despite any potential disappointment. 
 
 
A further example is one participant in the moderate range who revealed that he had 
trusted the doctors from the local CF team to initially provide the information he 
needed about the Run-in study: 
 
Well I didn’t really know a great deal about it. I’d just sort of been, find out from the 
doctors at the CF clinic. (Participant 9, lines 286-287) 
 
 
This suggested that knowledge of the gene therapy resea ch was important for the local 
CF team in helping it to facilitate participants’ exp rience of the trial.   
 
Participants trusted in sources of information in addition to the research team and local 
CF team. Half of the participants trusted the information from the CF Trust regarding 
the gene therapy trial, one showing that she found information from the research team 
and the CF Trust the most believable: 
 
The information from [the doctors and the CF Trust] are the things to believe in, 
straight from the horse’s mouth rather than circumstantial evidence. (Participant 8, 
lines 63-67) 
 
In contrast, one participant with a late diagnosis showed belief in the information from 
the research team and from the CF Trust but only in wr tten form. Whilst she appeared 
to trust both sources of information, the requirement of needing statements committed 
to paper indicated that there was some level of mistrust as well as trust, which may 
have reflected the participant’s anxiety. This need for confirmation helped her to 
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manage her expectations regarding the gene therapy tri l, thereby helping her to cope 
with the uncertainty regarding the outcome (Memo 32):  
 
When there’s a report sent [from the research team] saying this is what is going to 
happen, and this is the result, then I’ll believe it…. if I read it on the forum that the CF 
Trust have put it on [update on trial], then I mean they would never say anything if it 
hadn’t happened. (Participant 6, lines 215-218; lines 238-241) 
 
 
Sub-theme: Hoping gene therapy works for others in the future 
In this sub-theme, participants were trusting that ere would be an eventual, successful 
clinical benefit from either this trial or a future trial for other people with CF. By 
hoping for this benefit for others, participants showed altruism but also used hope as a 
way of being able to think ahead more comfortably i.e. without as much personal 
investment. In this way, hope and expectation worked dynamically since hope seemed 
to be more unreservedly expressed than when thinking of personal benefit and 
participants seemed to have a greater expectation of future success for gene therapy 
than of the imminent gene therapy trial.  
 
Analysis of the data (Memo 44) indicated that there was overlap between hoping for 
benefit for oneself in the future and hoping for the eventual benefit of others, one 
example being:  
 
So, you know that’s quite cool [helping a known child with CF]… and of course it 
might help me in the long run as well. Who knows? (Participant 3, lines 111-119) 
 
The researcher speculated that the hope of potential benefits from gene therapy 
treatment in “the long run” was a way of managing expectations by allowing for hope 
to continue beyond participation in the trial. This would be even more so if treatment 
outcomes of the imminent trial did not meet expectations, thereby helping participants 
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to have a strategy for dealing with disappointment. It was not always clear whose future 
was referred to in terms of receiving clinical benefit: 
 
[being chosen for active treatment] you would actually feel that there was a benefit and 
it would give you hope for the future that the product’s actually working. (Participant 8, 
lines 213-216) 
 
In the researcher’s memo (Memo 31), the role of altruism was explored and whilst it 
was present in seven accounts, only one of these partici nts expressed no hope or 
expectation of personal benefit. Another of these participants’ accounts demonstrated 
how participation may initially have begun with altruism being prominent but that 
another reason for participation may have emerged as selection for the gene therapy 
trial drew nearer:  
 
It maybe moves onto a slightly more personal level from a kind of, “This might help 
everyone with CF” to a, “Hang on, you know, it might elp me” [laughter]. 
(Participant 12, lines 815-818) 
 
Although there was evidence from the data that all twe ve participants were hoping that 
gene therapy treatment would benefit others with CF, only one highlighted that 
emotional maturity was required to be able to really do so: 
 
It will help generations in the future and I think it depends on your emotional 
confidence whether you can be glad for the benefit to others, or whether you’re still 
focussing on “It’s not going to do me any good”. (Participant 8, lines 111-1116) 
 
The same participant was managing awareness of potential personal loss based on the 
shortfall between previous expectations of gene therapy treatment and current reality: 
 
A lot of that PR spin that was about, you know, it’s like, “Let’s raise money to find a 
cure for CF” has really fallen away in the past five years to go to, “It’s an improved 
treatment” because people were so clinging on to the idea of gene therapy being so 
wonderful and it’s really not. (Participant 8, lines 79-86) 
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This highlights that wider expectations of gene therapy beyond the current trial were 
not without complexity since being able to hope for future benefit for others required 
some level of acceptance that the gene therapy product was not likely to be as effective 
for current participants. Indeed, maximum benefit was expected for children and those 
not yet born: 
 
I presume for children it’ll make a huge difference. They won’t have the lung damage. I 
presume for them that’s what is going to be the most important thing. (Participant 6, 
lines 58-62) 
 
For the new generation coming in, fantastic. They’r not even going to know CF as 
anything serious. (Participant 8, lines 95-98) 
 
The researcher’s analysis (Memo 45) indicated that six participants expected a “huge” 
or a “massive” difference for those in the future e.g. not having a life-threatening illness, 
greater longevity, reduced medication and not having lu g damage.  
 
Of the twelve participants, six expressed the hope of a future cure for CF, two of these 
combining expectation and hope in their responses. In the following example, the 
researcher considered that the participant was aware of the difference between hoping 
for a cure, which would happen in an ideal world, and expecting a cure, which would 
be based on the reality of research (Memo 23). Continui g research would bring that 
reality closer:  
 
 I’m not particularly expecting that in a year’s time there’ll be a cure, but, you know, 
obviously in an ideal world there would be. But, I think that all I would expect is that in 
a year’s time they’ll be closer. (Participant 3, lines 191-195) 
 
 
The remaining six participants hoped that gene therapy would potentially be a partial 
cure or an improved treatment. This is demonstrated by the participant below who 
expected the possibility of an improved treatment to keep the lungs stable. However, it 
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was unclear whether she was conflating her expectations with those she anticipated for 
the research team (Memo 35): 
 
I mean it may take a long time, longer than expected, but they’re still doing it. It’s not 
just in the planning stage or the thinking through stage, it is happening. (Participant 6, 
494-497) 
 
It may be that hopes for others in the future could be more safely managed, as 
exemplified in the following: 
 
If, you know, people have said, “How do you feel about it?” you know, I’ve always just 
had the mindset that it’s nice to know I’m part of a research for generations to come 
and not for me. (Participant 11, lines 206-210) 
  
Even though it won’t affect me, it will help the other CF patients and then from that 
they’ll keep on, getting closer to finding stuff about CF but not probably give it to us 
but to all other CF patients. (Participant 5, lines 348-355) 
 
However, given the scientific rationale for the gene therapy trial, participants were 
realistic in terms of thinking of the likelihood ofthere being much greater benefit for 
children and for those not yet born than for themselves. Nevertheless, one participant 
still allowed himself to hope for personal benefit whilst remaining realistic:  
 
I’m quite realistic about [the gene therapy trial], I’m not expecting it to be the wonder 






The findings of the current study are discussed in th s chapter in comparison with 
previous research. Suggestions for future research are also made. The chapter considers 
strengths and limitations of the current study, includes some reflections from the 
researcher and assesses the contribution made by th findings.  
 
4.1 Qualitative Findings 
 
4.1.1 Core Category: Expectations of Gene Therapy 
 Subcategory: Hoping gene therapy works for me 
 
The researcher found that ten of the twelve participants hoped that the gene therapy 
trial would have some clinical benefit for them. Participants from the current study 
hoped to benefit in a similar way to respondents in the survey by Duff (personal 
communication, 17 June 2009), albeit the latter were not participating or scheduled to 
participate in a gene therapy trial. Participants i both studies expressed the wish for 
reduced intravenous antibiotics and less chest infections. They also hoped that lung 
deterioration would slow down. The similarity of findings in both samples indicates 
that hopes of positive outcomes from gene therapy treatment are likely to be present 
before participation begins in gene therapy trials. The strength of hope increased for 
half the participants in the current study as they underwent the Run-in study (See Sub-
theme: Trusting in the system). As current findings have indicated, hopes of gene 
therapy being an effective treatment can increase by participating in a pre-treatment 
phase of a gene therapy trial.  
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This was in contrast to the findings by Blair et al. (1998, p.220) that “most patients” 
had a realistic understanding that they should not expect any personal clinical benefit 
from participating in the safety trial. One reason for this difference may be the 
awareness of participants in the current study that mul iple doses of the gene therapy 
product could produce clinical benefit, although the magnitude of this remains 
unknown.  
 
The levels of optimism for personal benefit from the current trial were higher than 
those in the Blair et al. (1998) study in which nine out of sixteen patients were “hopeful 
or very hopeful” of personal benefit from gene therapy (Blair et al., 1998, p. 219). This 
may reflect a higher level of optimism regarding gene therapy treatment after eleven 
further years of research progress and the prospect of a novel multi-dose gene therapy 
trial. Perhaps a similar level of expectation is reflected in Duff’s findings (personal 
communication, 17 June 2009) because it is based on sample opinions taken recently of 
CF patients. A high level of expectation of gene thrapy was shown with 83.2% of 266 
respondents being convinced that gene therapy would be a treatment within ten years. It 
was unclear what criteria respondents were basing their response on.  
 
However, some of the positive expectations in the current study are unlikely to be met 
by the gene therapy trial e.g. having CF symptoms removed completely, no longer 
requiring medication. Whilst it is difficult to evaluate these expectations, it is more 
realistic to expect that an effective product will take time to develop based on the 
difficulties to date in developing gene therapy forCF. Only two participants in the 
current study gave a clear time-frame for improved tr atment, the first positing that it 
would take at least ten years and the second between one to two years.  
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There is evidence to suggest that hope may be stronge  than expectation in participants 
undergoing participation in trials. High levels of ptimism about clinical outcome are 
present in extant literature. Despite the chance of clinical benefit in oncology phase one 
clinical trials being less than 5% (e.g. Daugherty e  al., 2000; Decoster et al., 1990; 
Hoff et al., 1991), vulnerable participants may have greater difficulty in distinguishing 
between the research and clinical aspects of a clinical trial (Daugherty et al., 2000). For 
example, in a survey interview study of 144 advanced ancer patients, 90% of people 
interviewed believed that they would experience clini al benefit as a result of active 
treatment despite having been informed of the low likelihood. In the current study, the 
magnitude of clinical benefit has been made less explicit and therefore may appear 
more possible. However, this does not explain the lower percentage (83%) of current 
participants actively hoping for clinical benefit than those (90%) in the study by 
Daugherty et al. (2000).  Yet the latter had a larger sample size, and patient populations 
were different therefore comparisons must remain tenta ive.  
 
Altruism was a motivating factor for seven participants in the current study. 
Participants in other trials have also reported the motivation to be altruistic, which may 
be due to identifying with future generations who will have the same condition. This 
sense of altruism is captured in the Blair et al. (1998) study, where it was reported as 
the main motivation for the majority of participants. Altrusim has been found as a 
motivation for participating in randomised clinical cancer trials (Jenkins & Fallowfield, 
2000). There is also evidence from a study on participation in HIV trials that the 
motivation for participating is for the potential future benefit for others, rather than 
necessarily for anticipated personal benefit (Wendlr et al., 2003). 
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However, only one of the seven participants in the current study who demonstrated 
altruism expressed no hope or expectation for personal benefit. This is similar to the 
finding that the motivation for trial participation is the hope of treatment having both 
personal benefit and benefit for others (Penman et al., 1984; Slevin et al., 1995).  
 
Hoping to participate in the trial 
Eleven out of twelve participants explicitly hoped to be selected for the gene therapy 
trial, nine of whom explicitly wished for active treatment and two of whom implicitly 
indicated this. Eleven participants explicitly said they were willing to be in the placebo 
condition. The overall level of willingness to participate corresponds to qualitative data 
that shows that interest in participation in gene th rapy trials is currently high. 
Respondents in the multi-survey study requested information on the progress of clinical 
trials and on how to become trial participants (A., personal communication, 17 June 
2009).  
 
Even if participants in the current study are not selected for the gene therapy trial, there 
is some evidence that rejection may not deter future participation. One participant in the 
current study said that he would try to be selected for another Run-in study, with hopes 
of selection for a future gene therapy trial. He remained optimistic about “just 
expecting something good out of it all” (Participant 5, line 489). In the study by Blair 
et al. (1998), three participants were not deterred from any future involvement despite 
being excluded from the gene therapy trial. They were marginally less optimistic about 
the potential for gene therapy for CF than those who had participated in the trial. Whilst 
this finding is tentative in both studies, it suggests that optimism about future 
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involvement in trials remains undiminished by not previously having been eligible for 
participation. 
 
4.1.2 Core Category: Managing Expectations 
 Subcategory: Strategies for managing expectations 
The current study indicated that participants on the Run-in study were employing a 
range of strategies to manage their expectations regarding an effective clinical outcome 
of the gene therapy trial. It was found that five participants were not raising their hopes 
about the outcome and four participants were not thinking too far ahead. It has been 
argued that the use of avoidance strategies has some benefit for short-term situations 
and there is some evidence to suggest that such strategies are adaptive when patients 
with CF are faced with a situation that is not able to be controlled (Abbott, 2003). It 
therefore may be that the strategies of not thinking ahead and of not raising hopes are 
adaptive when faced with the difficulty of not being able to predict selection for the 
gene therapy trial.  
 
In terms of possible continuing participation into the gene therapy trial, there is 
evidence that active coping strategies are more effctive for long-term situations 
(Abbott, 2003). However, these strategies work bestfor situations that are controllable. 
It is therefore not clear how the participants in the current study who use avoidance 
strategies to manage their expectations will continue to benefit if their participation is 
continued into the gene therapy trial.  
 
Yet the findings on coping strategies are not conclusive. Whilst there is evidence that 
different coping strategies may be used within chronic illness (Macdonald, 2006), 
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Abbott (2003) posits that it is more important to cnsider what is of most help for 
psychological functioning rather than strategies being adaptive or otherwise. The 
majority of participants on the current study had not experienced psychological 
difficulties during participation and indeed four had actively benefited from the 
experience through receiving clinical support. Therefore strategies to manage 
expectations were largely effective. Abbott (2003) suggests being aware of the match 
between expectation and outcome and of evaluating how strategies are working for 
individuals. It may be that the strategies of the participants will change over time (e.g. 
Lazarus & Folkman, 1984).  
 
In an earlier study of expectations of gene therapy, only one out of sixteen patients on a 
single dose safety trial used the strategy of not thinking about gene therapy too much in 
case anxiety about it increased (Blair et al., 1998). This was in the context of managing 
associated anxieties about gene therapy treatment rather than managing positive 
expectations of it. Indeed in Blair et al. (1998), there was a significant minority of 
patients who had anxiety disorders, being more likely to be worried about the safety 
and potential of gene therapy treatment. The two patients in the current study who were 
anxious were concerned about missing the potential of the active treatment but were not 
worried about the safety aspect of treatment. However, this highlights the importance of 
eliciting feelings and opinions of participants on trials to gain valuable information 





4.1.3 Sub-theme: Trusting in the system 
 Trusting the gene therapy product 
In the current study, participants’ trust in the gene therapy product grew as they became 
aware of the researchers doing something bigger and more real than they had first 
thought. There was evidence of six participants whohad seen an increased expectation 
of gene therapy being an effective treatment, one having confidence in the product 
being developed safely for use. Optimism among Blair et al. (1998)’s sample for an 
effective gene therapy treatment in the future was also high. Whilst an increasing sense 
of optimism about gene therapy was reported by a third of 266 respondents in Duff’s 
study (A. Duff, personal communication, 17 June 2009), data being collected during 
2007, the majority ranked their level of optimism as neutral (44%). It may be that 
participation in a trial is an influential factor in increasing optimism about the 
effectiveness of the gene therapy product, since there is still optimism in Blair et al. 
(1998)’s sample when the product was much less developed than to date.  
 
The researcher did not ask participants in the current study whether they had any 
concerns regarding the gene therapy product. In the Blair et al. (1998, p.220) study, 
twelve patients did not report being adversely affected by participation in the single 
dose gene therapy trial and “almost all” believed themselves to have been at no risk 
from the product. For the six participants in the current study who had seen no change 
in expectation, only two referred to waiting until the gene therapy product worked 
before they could trust in it as a product. There was no mention that the product might 
not be developed safely.   
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Hoping gene therapy treatment works for others in the future 
It is useful to consider the sub-theme “Hoping gene therapy treatment works for others 
in the future” at this point because of its clear link to how participants manage both 
hope and expectation about gene therapy. 
 
There was overlap between hoping for benefit for oneself in the future and hoping for 
the eventual benefit of others. Six participants expr ssed the hope of a future cure for 
CF and six believed gene therapy to potentially be a partial cure or an improved 
treatment. This differed from a study by Thomas et al. (2007) who found that adults 
with CF did not seem to believe that gene therapy would be a potential cure. It may be 
the case that participants’ involvement in the Run-in study had an impact on these 
beliefs.  
 
Of the twelve participants, there were six who expected that future gene therapy 
treatment would make a “huge difference” for those with CF, anticipating that future 
generations would not have to suffer the life-limitng effects of CF and that less 
medication would be required to manage the condition. Of these participants, four 
explicitly based their reasoning upon empirical knowledge, albeit not in any depth. This 
finding contrasted with the Blair et al. (1998, p.219) study where fifteen out of twenty 
patients gave a positive estimate that gene therapy would effectively treat CF in the 
future. Instead of basing this on critical evaluation of evidence, fourteen of these 
participants based this on “gut feeling.”  
 
 
In the current study, participants expected that gene therapy would have the greatest 
benefit for children before the development of lung damage. This is similar to findings 
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in Blair et al. (1998) where babies and young children were anticipated to benefit the 
most from treatment before the development of permanent lung damage. In the findings 
by Duff (A. Duff, personal communication, 17 June 2009), the majority of participants 
(83.7%) believed that those currently aged five andu er and future generations would 
be the beneficiaries of gene therapy.  
 
 
One explanation for participants in the current study concurrently demonstrating 
altruism and expectation of personal benefit is that ere was participant perception of 
researchers looking for clinical benefit from the multi-dose gene therapy trial. This is 
compared to there having been no such expectations within the earlier single dose trial 
(Blair et al., 1998). Nevertheless, when participants in Blair et al.’s (1998) study were 
asked whether they expected to benefit personally from gene therapy in the future, five 
expected fewer chest infections and reduced medication, five expected disease stability 
and three hoped for improvement in their lungs. Participants were therefore expressing 
an expectation of gene therapy that was similar to participants’ expectations of personal 
benefit from the gene therapy trial in the current study. 
 
In the current study, one participant’s concern about being well enough to receive gene 
therapy treatment in the future finds resonance with the findings from Duff where 
almost one third (31.14%) of all 266 respondents thoug t that it would be those whose 
health was “well above average” that would benefit compared to 20.18% who believed 
that it would be beneficial for those of “poor health.”. 
 
It is therefore clear that unlike the above studies, participants in the current study did 
find that both their expectations and hopes about gene therapy were raised. This seems 
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to be linked to actually participating in a trial tha  will potentially lead to a gene therapy 
trial as well as their experience of visiting Southampton where they had contact with 
new technology which made the trial seem much more ‘real’ to several participants. 
 
Participants therefore did have expectations and hopes of participating in the gene 
therapy trial and of obtaining some clinical benefit from it, as well as hope in the gene 
therapy product in the future. As has been discussed, they have managed these 
expectations by not thinking too far ahead and not raising their hopes too high. 
Participants also found the ongoing trusting relationships they had with the research 
team, their local CF teams and the CF Trust as very useful coping strategies to manage 
these hopes and expectations. 
 
Trusting the research team and the information they provide 
Participants in the current study expressed a general s nse of trust in the research team, 
including trust in their selection procedures for the gene therapy trial and in their ability 
to deal well with participants’ enquiries. Trust was lso strengthened through other 
perceived clinical benefits obtained from being on the Run-in study. Wendler et al. 
(2003) indicate that participants generally trust research teams. There is evidence that 
patients invest trust in the professionals running clinical trials even before meeting 
them (Jenkins & Fallowfield, 2000). There is also evid nce of patient trust in doctors 
involved in clinical trials and this has been given as a frequent and stable reason for 
participation in cancer trials (Penman et al., 1984). 
 
 Although two participants in the current study refe red to being a “guinea pig,” the 
researcher understood use of this word in a light hearted way meaning the undertaking 
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of study visits and test requirements as directed. There was no indication that 
participants had lost trust in how the research team was using their contribution to the 
trial. This is in contrast to situations where patien s are treated inappropriately by 
clinical research teams as merely objects i.e. as something to be acted on (Jonas, 1969) 
 
Of the twelve participants in the current study, ten had not asked the research team for 
any extra information to the initial information they had been provided with, although 
three of these expressed confidence that the team would be able to deal well with their 
enquiries. This was the same finding in Blair et al. (1998) where three participants felt 
that they would be able to ask for more information f desired. Some studies have 
shown that clinical research teams may take advantage of their participants’ lack of 
understanding of research procedures (Wendler et al., 2003). However, there was no 
evidence of this in the current study, and participants did not appear to feel the need to 
fully understand gene therapy as a pre-requisite of participation. It may well be that, for 
participants, managing the amount of information they ad about gene therapy was a 
way of managing their expectations about gene therapy. However, they were very 
comfortable with asking the research team, their local CF team or the CF Trust if they 
had any need to find out further information. 
 
There was evidence of participants believing information from the medical research 
fellows in the research team because of their privileged position regarding knowledge. 
This corresponds to the suggestion by Lidz & Appelbaum (2002) that participants in 
clinical trials bring prior expectations of the doct r-patient relationship to participation 
in the trial. However, one of the participants in the current study did indicate a level of 
frustration in trying to ascertain the research outc mes of the trial. Whilst there was not 
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sufficient evidence to say that this was a clear case of research goals differing between 
participant and researcher (Lidz & Appelbaum, 2002), it is more likely that the 
expectations of the participant exceeded those of the researchers. The participant 
recognised that there was uncertainty regarding the outcome of the trial yet appeared 
unsatisfied due to information not being “freely given” to help with his own uncertainty. 
This raised the question of how both participants and research teams manage 
uncertainty in the development of novel therapies and how participants are helped to 
manage their hopes and expectations. 
 
Trusting local CF teams and the CF Trust 
In the current study, five out of twelve participants showed evidence of trust in their 
local CF teams during their participation in the Run-in study, indicating that whilst they 
would look for information about gene therapy from the research team, they would also 
discuss aspects of the trial with their local CF teams. This finds support in the findings 
by Thomas et al. (2007) with most respondents wishing to discuss gene therapy further 
with their local CF teams, although the largest source of information for two-thirds of 
the respondents was the UK CF Trust (Thomas et al., 2007). 
 
Moos and Holahan (2007) have identified that people with chronic illness have to 
undertake the adaptive task of forming relationship with health care providers. This is 
evidenced in patients with CF who often have ongoin relationships with their local CF 
team. It is therefore an interesting finding that prticipants felt they benefited from the 
support of their local CF teams as they participated in the Run-in study.  
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Further, in Duff’s findings (A. Duff, personal communication, 17 June 2009), 
respondents indicated that they would like more information about gene therapy 
routinely given to them by their local CF teams andthat they wanted this information to 
be clear and realistic i.e. not giving false hope aft r having waited so long for gene 
therapy. Closer liaison therefore between the reseach team and the local CF teams 
could be useful, especially at key stages of the res arch process.  
 
Half of the participants in the current study trusted he information from the CF Trust 
regarding the gene therapy trial and would continue to trust the CF Trust as a reliable 
source of future information. This is similar to the findings by Duff (A. Duff, personal 
communication, 17 June 2009) where 58.9% of respondents cited the CF Trust as one 
of the most common trusted sources of information for participants. However, 69.2% of 
the respondents overall considered the CF local team o be the most important source of 





The findings of the current study indicate that participant experience of the Run-in 
study was influenced to some extent by time of diagnosis. Little has been known about 
the specific needs of those diagnosed with CF as adults (Widerman, 2003). However, 
there is evidence to suggest that there are different stages of adjusting to diagnosis 
made in adulthood, one of which is that of male patients coming to terms with 
infertility. This issue emerged in two males who had been diagnosed late, although one 
said that it was “water under the bridge” (Participant 2, line 124), having come to terms 
with infertility and with his diagnosis. However, the other male participant was still 
coming to terms with his much more recent diagnosis. Widerman (2003) recognises 
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that local CF teams should assess the needs of those with late diagnosis and help 
patients to address these needs. It may be that patients who participate in the trial with a 
relatively recent diagnosis have their hopes or indeed expectations of a cure influenced 
by the process of continuing adjustment to diagnosis.  
 
Indeed, the two most recently diagnosed participants, both of whom were diagnosed 
within the last five years, were more hopeful of personal benefit from the trial than 
those who had received an earlier diagnosis as an adult. They also appeared to be more 
anxious that the trial succeed, one of these being the participant who became upset 
about the possibility of not being able to participate in the gene therapy trial. However, 
it may also be the case that participants with late diagnosis perceive that they are too 
well to receive physical benefits from the trial, with the two remaining participants with 
late diagnosis indicating this in their responses.  
 
It has become clear to the researcher that people with CF who would potentially 
participate in gene therapy trials could include different groupings of patients e.g. those 
who have had a late diagnosis, those whose CF is seen as mild, those who are in the 
moderate category whose realistic chance of benefiti g from gene therapy may be 
restricted, and those who are children. Jaffe et al. (2006) highlight the complex family 
dynamics at work in including children in clinical research. The differing needs and 
vulnerabilities of these various groups should be considered when offering support to 
those participating in gene therapy trials in the future.  
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4.2 Summary 
The main aims of the study were to discover the expectations that participants recruited 
for the CF Run-in study had of the gene therapy trial and of gene therapy in general and 
to ascertain whether these expectations changed during their participation in the CF 
Run-in study. This included whether participants had any misconceptions of gene 
therapy. Difficulties and benefits of participation i  the Run-in study were also 
explored.  
 
Eleven out of twelve participants explicitly express d the hope of being selected to 
participate in the gene therapy trial. The researcher found that ten of the twelve 
participants hoped that the gene therapy trial would have some clinical benefit for them. 
Four of these participants said that they did not have any expectations or did not know 
what to expect. The remaining two participants said that they did not expect personal 
benefit but still expressed hope that the trial would work for those known to them or 
those in the future.  
 
Half of the participants expressed the hope of a future cure for CF delivered by gene 
therapy and six participants hoped that gene therapy would potentially be a partial cure 
or an improved treatment. Six participants had an increased expectation of gene therapy 
being an effective treatment in the future. It was anticipated that gene therapy would 
have the greatest benefit for children and young people before the development of lung 
damage.  
 
Six participants’ hopes of getting clinical benefit from the gene therapy trial were 
unlikely to be met e.g. experiencing stable lung function, living a normal life or having 
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CF removed altogether. There was therefore some unralistic optimism in half the 
participants on the current study. However other patients participated with apparently 
realistic expectations. Participants utilised coping strategies such as not thinking too far 
ahead, and not raising their hopes too much, as well as relying on the research team, 
their local CF team and the CF Trust to help manage these expectations. 
 
Time of diagnosis may also have had an effect upon participants’ experience of the trial 
and whether or not they experienced psychological difficulties or physical benefits. 
This underscores the need for attention to be paid to the different groupings of patients 
who may be participating in the gene therapy trial so that adequate support is put in 
place. Most participants found participation in theRun-in study a positive experience 
and four had experienced clinical benefits from participation.  
 
Altruism was a motivating factor for seven participants in the current study and it 
seems likely that some patients would have participated even if there were no prospect 
for personal direct benefit from gene therapy. There was evidence of six participants 
who had seen an increased expectation of gene therapy being an effective treatment in 
the future. 
 
4.3 Reflections on the Research Process 
 
4.3.1 Participants’ Perceptions of Being Interviewed 
As outlined above (Section 2.6.2: Interview Procedur ) eleven out of twelve 
participants were asked about how they had found the experience of being interviewed. 
No participant commented on how they had found the experience of being interviewed. 
Five participants commented that the interview process was “fine,” “okay” or “all 
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right.”  In addition, two of the twelve participants said that they had not known what to 
expect and two explained that they had found it hard to express their thoughts in words. 
Whilst one found the interview how he had imagined, another found it different to what 
he expected i.e. something “more, I don’t know, conversational” (Participant 2, lines 
432-433). One participant thought the researcher would be asking questions about CF 
and his own health behaviour. The remaining participant found that the interview 
process had helped him to reflect on his participation in the Run-in study:  
 
You know it’s not very long, it’s only what half anhour but you’ve still just that little bit 
time to sit down and talk to somebody else about it and just think maybe what you 
actually feel about the whole thing a little bit more in-depth. (Participant 12, lines 894-
899) 
 
None of the participants expressed negative thoughts or feelings about being 
interviewed. Prior to interview, one of the participants who found it difficult to express 
himself verbally had alerted the researcher to thisfact but he indicated that he still 
wanted to help the study.  
 
4.4 Researcher’s Reflections on the Interview Process 
The researcher was aware of the role that her own values, interests and presuppositions 
could play in directing the course of the interview. For example, the researcher was 
interested in one participant’s experience of teachr training because she herself had 
trained as a teacher. Whilst discussion of a topic f mutual interest was helpful for 
building rapport, the length of discussion was slight y long. This was an example of 
possible bias though it was likely to be benign in terms of the research aims.  
 
The researcher recognised that during the process of interviewing twelve participants, 
she experienced a growing sense of hope about the possibility of an effective gene 
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therapy treatment for CF. However, the researcher tri d not to use language that 
reflected this sense of hope although she was aware that tone of voice or facial 
expression might have indicated a shared sense of hope with the participant being 
interviewed, especially in the latter stages of the study. The researcher was also aware 
of the investment of the research team in the gene therapy product and recognised that 
she did not want to disappoint them with findings that did not fit with their own hopes 
of gene therapy being developed. This emerged more clearly during the researcher’s 
analysis in her memo writing; it also emerged in discussion with her academic 
supervisor which helped to make implicit bias more explicit.  
 
The researcher reflected on the need to balance an interview in terms of building 
rapport, being responsive to the interviewee’s interests and leading the interview. The 
researcher recorded in her methodology diary that se used follow-up questions to 
encourage participants to explain their definition of words or expressions e.g. “having a 
normal life.” This was because the researcher wished to avoid using her own 
assumptions in interpreting expressions participants used, albeit she acknowledged her 
role in the interpretive understanding of the data.  
 
The researcher also tried to help participants to relax prior to interview as she was 
setting up the digital voice recorder. The researcher used this time to begin to gauge 
how best to minimise any inequalities that would be detrimental to the interview 
process e.g. to reduce any effects of an age differenc  between researcher and 
participant. The appropriate interview approach for each participant was chosen, based 
on the researcher’s previous teaching and clinical experience and thus encouraging the 
participants to be research collaborators. The resea ch r worked with participants to 
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maximise the opportunity for them to respond to questions. For example, when 
participants found that it was difficult to explain something, the researcher helped the 
participant to approach the issue from a different angle e.g. “If your family or friends 
asked you what you know about gene therapy, how would you explain it to them?”  
 
The researcher evaluated her interview technique after each interview to assess her 
influence upon the interview process e.g. whether s asked any leading questions or 
whether there was an appropriate balance between listening and speaking. As a result 
the researcher developed her interview techniques ov r the course of the current study, 
resulting in decreased speaking time and increased li tening time for the researcher. 
Participants were asked how they had found the interview experience and these 
responses were recorded from interview three onwards, the researcher having realised 
the benefit of a verbatim record of the participant’s evaluation of the interview. This 
was with the aim of encouraging participants as research collaborators. As the last 
interview was brought to a premature close, this reflective process was not able to be 
undertaken (See Section 2.6.2: Interview Procedure). 
 
4.5 Methodological Considerations 
The researcher recognises that there were methodological limitations and strengths in 




The methodological limitations identified are as follows: the researcher having limited 
experience of qualitative research, respondent validation and selection bias.  
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4.5.1.1 Researcher’s Limited Experience of Qualitative Research 
The researcher acknowledges that limited experience of qualitative research has had an 
influence upon how the current study has been undertaken. The researcher scheduled 
the first few interviews within a relatively short time frame, although this was also due 
to arranging interviews at the convenience of the participants. Further, the time taken 
for the current study to go before an ethics panel was prolonged due to significant 
consideration of whether it should be a substantial amendment to the Run-in study or a 
separate study. The latter was eventually decided after discussion with both the 
Edinburgh and London research sites.  
 
It was likely that the earlier interviews conducted were limited by the researcher’s 
inexperience in not asking sufficient follow-up questions to generate rich data from the 
participants. However, the researcher developed additional questions to saturate 
emerging themes and she acknowledges that pure data saturation may not have been 
achieved (See Section 2.1.4: Process of Grounded Thory).  
 
Whilst the researcher aimed to follow a Grounded Theory approach, she acknowledges 
that she did not follow axial coding as outlined by Strauss and Corbin (1998). Further, 
the interview schedule was not sufficiently flexible to follow through on areas of 
interest raised within the interviews such that these were not explored as thoroughly as 
they would have been within a traditional Grounded Theory approach e.g. examining 
the difference between hope and expect in more depth and developing these findings as 
a potential category or concept.  In addition, the semi-structured nature of the interview 
schedule was more characteristic of an Interpretative Phenomonological Analysis (IPA) 
approach to exploring and gathering data (e.g. Smith & Osborn, 2003).  
 109 
All interviews were recorded accurately, except for one in which the digital voice 
recorder’s file reached capacity and the last three minutes approximately were not 
recorded. On realising this immediately following the interview, the researcher 
recorded by hand what had been said with the recogniti n that this was not exactly 
verbatim in the manner of a digital recording.   
 
4.5.1.2 Limited Respondent Validation: Preliminary Findings 
Although the use of respondent validation is an undo bted strength in qualitative 
methodology and the researcher had sent out preliminary findings for participants’ 
comments, only one participant commented on these findings. His comments were that 
participants had given “neutral statements regarding expectations”: 
 
Clearly nobody wants to be seen to step out of line with how they 'think' you'd like them 
to respond. In other words everyone has to be drawn to the middle. As for myself, I 
remain very positive that gene therapy might well b my meal ticket. If I receive gene 
therapy, I expect something to happen, assuming something happens, I expect it to 
be for the best, therefore: gene therapy will positively affect me... 
 
It is acknowledged that the intention and process of respondent validation was a 
potential strength methodologically. The researcher felt that because of the small 
number of responses this could be a potential limitation. However, following 
dissemination of the full findings, seven participants gave comment on the findings 
(See Section 4.5.2.5: Respondent Validation: Final Findings)  
 
4.5.1.3 Selection Bias 
Participants on the current study had been invited to participate in the CF Run-in study 
because of the main criteria that they had mild to moderate disease severity. Thus those 
with more severe disease were inherently excluded from the study. In discussion with 
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the research manager for the Run-in study, it was ascertained that the twelve 
participants were representative of the Run-in sample as a whole in terms of disease 
severity, age, gender and geographical location.  
 
Of the forty-two participants on the Run-in study, twelve chose to be interviewed for 
the current study. It may be that these self-selecting participants were more willing or 
were more available to discuss their expectations of gene therapy and what it was like 
to be a participant in the Run-in study. This could have limited the researcher’s access 
to other perspectives on expectations, the level of support other participants might have 
required, or experiences of participation e.g. those who had doubts about continuing 
participation in the Run-in study.  
 
4.5.2 Strengths 
Although there were limitations, the researcher posits that the current study also 
displayed significant strengths. These will be considered in the following order: clear 
communication with the research team, qualitative methodology, ethical rigour, 
theoretical sampling, effective supervision and reflection.  
 
 
4.5.2.1 Communication with the Research Team 
The researcher maintained good communication with the research team throughout the 
study. The researcher gave a presentation on her proposed study prior to undertaking 
interviews. She kept up-to-date with the progress of the Run-in study and discussed 




Whilst there were limitations in terms of possible ias and the researcher’s initial sense 
of constraint on producing results which she perceived as contrary to the interests of the 
team, the researcher worked to minimise these limitations. The researcher found that 
the strengths of being involved with the research team were greater than managing 
possible bias e.g. gaining information on the progress of the study and having queries 
answered regarding the nature of gene therapy for CF.  
 
 
4.5.2.2 Qualitative Methodology 
The use of qualitative methodology in the current study enabled participants to openly 
discuss their experiences on the trial and their expectations of the gene therapy trial and 
of gene therapy in general. This gave insight into their expectations, how these were 
being managed and into why expectations had changed or remained stable. It also 
identified areas where benefits and/or difficulties were experienced through 
participation in the Run-in study.  
 
4.5.2.3 Ethical Rigour 
The researcher contends that the current study was undertaken professionally and with 
due consideration of the participants’ best interests, as outlined in 2.3 of the Method. 
The researcher monitored participants’ responses to ensure their well-being. 
Participants were aware that support was available should this have been required.  
 
4.5.2.4 Theoretical Sampling  
As a method-based qualitative approach, grounded thory uses theoretical sampling 
after coding and analysis to identify gaps in the developing theory. Based on this, the 
researcher identifies the data that needs to be collected in order to supply this 
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information and then develop and refine theory (See Section 2.1.4: Process of 
Grounded Theory). In theoretical sampling, research participants or research topics are 
strategically selected to fill the gaps identified. In the current study, there was a limited 
available pool of potential participants such that it was not possible to fully select 
participants purposefully. For example, the researcher’s sample was representative of 
the age group within the Run-in study but the researcher would have liked to have 
recruited more participants with late diagnosis for theoretical sampling.  
 
Nevertheless, the researcher was able to develop questions for subsequent interviews in 
order to explore as much as possible the full range of r sponse within the subject area. 
The researcher acknowledges that earlier detail mayhave lead to a more developed 
initial framework yet later data was rich and still a owed for the development of 
categories and subcategories.  
 
4.5.2.5 Respondent Validation: Final Findings 
There were seven participants who expressed several opinions on the final findings. 
Three participants found the current study to be int resting. There were three who 
commented that the findings were as expected, with one making the additional 
comment that the results were balanced. Three participants believed that the 
expectations of the gene therapy trials expressed in the current study were largely 
similar. One participant believed that it would be interesting to compare the views of 
the researchers and the participants. Two participants found the study provided a good 
opportunity to thank about aspects of the trial. Another commented on having a sense 
of ownership in the gene therapy trials. A further comment from one participant was 
that it was a “shame” that the research was behind schedule.  
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4.5.2.6 Effective Supervision 
Meeting regularly with both the researcher’s academic and clinical supervisor 
respectively ensured that the researcher’s qualitative skills developed effectively and 
that issues arising from the interview process were explored thoroughly. The researcher 
benefited from the support of both supervisors. Following initial independent coding by 
both supervisors, the joint meetings in which coding a d themes were discussed were 
very useful in clarifying important data and processes. The experience of both 
supervisors added to the quality of the research. One was a chartered health 
psychologist with qualitative research experience in the health field and the other a 
chartered clinical psychologist with substantial exp rience in CF. 
 
 
4.5.2.7 Researcher’s Reflection  
The researcher used separate reflection and methodology diaries to keep notes of 
reflections on the researcher’s own practice, observations of participants during 
interviews, and of amendments made e.g. adding questions to the interview schedule. 
The researcher was aware of being in a privileged position by being allowed into the 
participants’ world. The researcher was also very aware of not having CF and 
maintained a respectful attitude throughout the intrview process.  
 
. 
Experience of working as a trainee clinical psychologist with patients with CF informed 
the researcher’s approach to the interviews and helped her to have a context in which to 
make sense of the participants’ responses. This would have been very difficult without 
knowledge of the progressive nature of CF and of the treatment required, and of how 
patients with CF vary in managing their condition.  
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The researcher was also aware of the different stage  of CF. For example, she became 
conscious of three participants in young adulthood being dependent upon parental 
support, this often being a protracted period of transition to independent adulthood. The 
researcher was helped to analyse the material from all the interviews by considering the 
different life cycle stage of each participant.  
 
However, she did not wish to assume how a participant was experiencing CF and 
indeed how this would influence their expectations f gene therapy and participation in 
the trial. The researcher was mindful of always encouraging the participants to tell their 
own stories. Nevertheless she acknowledges that previous knowledge of CF may have 
unconsciously influenced how she perceived the participants.  
 
 
Being a trainee clinical psychologist also helped the researcher to manage the 
sometimes intense emotions expressed. The researcher beli ved that her clinical 
psychology training greatly helped her in dealing with moving accounts, ethical issues 
and significant silences. Further, it helped her to ask questions sensitively.  
 
The researcher’s experience of individual work as a teacher helped her to engage 
participants quickly and at a level that was appropriate to them e.g. showing interest in 
their responses and taking their comments seriously. Teaching experience also helped 
her to use a different interviewing style from that used in therapy. On the three 
occasions when interviews began to move towards a therapeutic mode, the researcher 
was able to handle the tensions between monitoring participant well-being and not 
interviewing as a therapist.  
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In discussing gene therapy with colleagues within a local CF team, the researcher 
realised the variety of perspectives and knowledge re arding the likely effectiveness of 
gene therapy for CF. This helped her to reflect on the impact that such a new and 
developing field has upon the professionals who may be called upon to answer 
questions when the outcomes are not yet known. The res archer reflected that her role 
was to remain neutral when participants’ were describing expectations of gene therapy 
treatment. This was in order to elicit their accounts openly and without bias. 
 
The researcher also reflected upon her own level of kn wledge of gene therapy and 
how this might have affected the current research.  In interviewing participants the 
researcher was struck by the occasions when they assumed greater knowledge of gene 
therapy on the part of the researcher than was actually the case. Whilst the researcher 
helped participants to understand her limited knowledge, she did at these times wonder 
how far participants perceived her as being separate f om the Run-in study. However, 
whilst she did not perceive that participants were answering questions to influence 
positive selection for the gene therapy trial, she acknowledges that this might have been 
an implicit process.  
 
4.6 Contributions of this Study  
 
The researcher posits that the current study contributes to existing research in the five 
following ways:  
 
1. Discovering that participation in a Run-in study alone is sufficient for some 
 participants to develop increased expectations of gene therapy treatment i.e. 
 clinical benefits for themselves and for future generations;  
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2. Discovering that there is evidence of unrealistic optimism regarding the level of 
 likely personal benefit from gene therapy treatment .g. having all CF 
 symptoms removed; 
3. Discovering however, that participants use a variety of strategies to manage 
 their expectations of gene therapy e.g. not raising their hopes and not thinking 
 too far ahead;  
4. Discovering that participants may require support if they are not selected for the 
 gene therapy trial or for when the trial comes to an end; 
5. Discovering that there may be a difference in how participants experience the 
 trial dependent upon time of diagnosis and adjustmen  to this; and 
6. Discovering that participants are relying on the support of their local CF teams 
 during the Run-in process.  
 
 4.6.1 Clinical Implications  
Based on the above findings, and in consultation with the researcher’s clinical 
supervisor, the following recommendations are made:  
1. A standard clinical interview should be offered for all those not accepted for 
 gene therapy trial;  
2. A standard clinical interview should be offered at the trial’s conclusion; 
3.  Screening for anxiety pre-, during and post-paricipation should be undertaken. 
 This could mean adding in a validated screening tool such as the Hospital 
 Anxiety and Depression Scale (HADS) (Zigmond & Snaith, 1983) with the 
 Quality of Life measurement already given to participants at key stages of the 
 research process; 
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3. Screening for participants with late diagnosis should be done to identify those 
 who are still in the process of adjusting and may find participation more 
 difficult. This may also include identifying other participants who may need 
 more focused support; and 
4. Continued good communication between local CF teams and the research team, 
 with information continuing to be provided between t ams.  
 
4.6.2 Future Research 
The findings of the current study indicated areas for future research. Due to the finding 
that there was increased expectation of gene therapy t eatment in half of the participants 
on the Run-in study, extended study into the expectations of participants on the gene 
therapy trial would explore factors that influence expectations and how these are 
managed e.g. whether expectations increase with the 50% possibility of receiving active 
treatment.  
 
Due to the emergence of some specific findings dependent upon late diagnosis, it 
became clear that participants in gene therapy trials could potentially be grouped e.g. 
those who have had a late diagnosis, those whose CF is seen as mild, those who are in 
the moderate category whose realistic chance of benefiting from gene therapy may be 
restricted, and those who are children. The differing needs and vulnerabilities of these 
groups should be considered when offering support to hose participating in gene 




Greater optimism was noted by participants in the current study about the potential of 
gene therapy, compared to that found by Blair et al. (1998) and Duff (personal 
communication, 17 June 2009). Some of the positive expectations are unlikely to be 
met by the gene therapy trial but there was also evidence of apparently realistic 
expectations. Participants managed expectations by utilising individual coping 
strategies as well as through ongoing trust in the res arch and local CF teams. There 
was evidence of expectations of gene therapy increasing as a result of participation in 
the Run-in study. Most participants were realistic that true benefit from CF gene 
therapy may ultimately be for future generations.  
 
In general participants found being in the Run-in study a positive experience, although 
those with late diagnosis could be a group who may need support in managing their 
expectations about participation in gene therapy trials. Further research is needed with 
this group in terms of whether they have adjusted to iagnosis sufficient to facilitate 
participation in gene therapy trials. Consideration c uld also be given to other groups 
who participate in gene therapy trials who may benefit from support e.g. participating 
children and their parents.  
 
A recommendation is made for further support and a clinical debrief interview to be 
given to participants on this trial and future gene th rapy trials especially at key points 
e.g. if they are not selected, or when the trial comes to an end. The recommendation is 
made that a validated measure for screening mood such as the HADS be added in to the 
existing Quality of Life measure participants are completing as part of the Run-in study 
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which will assist in identifying low mood or anxiety and enabling appropriate support 
to be put in place. 
 
The researcher acknowledges that given the small sample size of participants, further 
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